Patent Grant
11279922
A Sequence Listing accompanies this application and is incorporated herein by reference in its entirety. The Sequence Listing was filed with the application as a text file on Dec. 14, 2012.
Delivery of therapeutic agents to sites within the body of a subject where a particular therapeutic agent is needed in order to be effective is a developing area. Such delivery systems will allow more efficient use of therapeutic agents while reducing toxicity caused by some therapeutic agents. Use of targeted liposomes or polypeptides, such as antibodies, to target therapeutic agents to particular sites within the body has proved successful, but additional delivery agents are needed.
Alopecia (hair loss) is a psychologically and emotionally distressing event with multiple causes. Alopecia occurs most commonly in male-pattern baldness, affecting approximately two thirds of males by age 35; a similar pattern of hair loss can be observed in females with polycystic ovarian syndrome. In both of these disorders, the hair loss is androgen mediated. Alopecia can also occur as an autoimmune disease, termed alopecia areata; a disorder which affects 1.7% of the population. It can occur as a side-effect of medical treatments, particularly in chemotherapy, with 65-85% of chemotherapy patients experiencing some degree of alopecia. Psychological consequences of hair loss have been well studied in the chemotherapy setting. Chemotherapy-induced alopecia (CIA) can result in anxiety, depression, a negative body image, lowered self-esteem and a reduced sense of well-being. In fact, 47-58% of female cancer patients consider hair loss to be the most traumatic aspect of chemotherapy, and 8% would decline treatment for fear of hair loss. In addition to these studies in chemotherapy patients, evidence exists in other forms of alopecia to support therapy to reduce psychological consequences of hair loss. Thus a new treatment to stop hair loss or speed hair regrowth would be beneficial.
While drugs with mild anti-androgenic effects (i.e. spironolactone) had been used with limited success as therapy for alopecia, the first effective medication for alopecia was minoxidil (Rogaine). This antihypertensive has an observed side-effect of causing hair growth, and is now used as topical therapy for many forms of alopecia. However, responses are incomplete, with some subjects showing only slowing of hair loss rather than actual regrowth. Finasteride (Propecia) is a newer agent that blocks conversion of testosterone to dihydrotestosterone, resulting in improvements in androgenic alopecia at the expense of partial systemic androgen blockade. However, response rates with long-term (10 years) therapy are only around 50%. Overall, despite considerable research in this area, there is still no adequate therapy for hair loss.
In addition, unwanted hair growth is a cosmetic issue many people deal with on a regular basis. Unwanted hair growth on the face, legs, arms, chest or back is a growing cosmetic problem. Many people use laser therapy, waxing or other therapies to remove unwanted hair. There are currently no topical pharmaceuticals to limit hair growth.
Collagenopathies represent a large number of diseases in which collagen structure or formation is not normal. This group of diseases results in a broad spectrum of symptoms including bone defects, vascular defects, and skin defects. Many of these diseases have no or only ineffective treatments available.
For example, osteogenesis imperfecta (OI), also known as brittle bone disease, is caused by an inborn mutation of type I collagen. Approximately 25,000 to 50,000 Americans are affected and the effects of the disease range from mild, in which many individuals are unaware of the disease, to severe in which individuals cannot live a normal life due to recurrent broken bones. Most OI patients carry a mutation which causes an amino acid change in collagen changing a glycine to a bulkier amino acid which results in disruption of the triple helix structure of the collagen and under-twisting. The body may respond by hydrolyzing the collagen and this may result in a reduction in bone strength. There is currently no cure and few treatments for OI.
Provided herein are methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF) and the bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen.
In another aspect, methods of treating a subject with a collagenopathy, such as osteogenesis imperfecta, by administering a composition comprising a bacterial collagen-binding polypeptide segment linked to a PTH/PTHrP receptor agonist to a subject in an amount effective to treat the collagenopathy are provided. The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen.
In yet another aspect, methods of treating hyperparathyroidism by administering a composition comprising a bacterial collagen-binding polypeptide segment linked to a PTH/PTHrP receptor agonist to a subject are provided.
In still a further aspect, methods of slowing hair growth or regrowth after removal by administering a composition comprising a bacterial collagen-binding polypeptide segment linked to a PTH/PTHrP receptor antagonist to a subject are provided.
In a still further aspect, methods of increasing hair growth or the speed of hair re-growth after removal or loss by administering a composition comprising a bacterial collagen-binding polypeptide segment linked to a PTH/PTHrP receptor agonist to a subject are provided.
Methods of delivering a therapeutic agent by administering a composition comprising a bacterial collagen-binding polypeptide segment linked to a therapeutic agent to a subject in need of treatment with the therapeutic agent are provided herein. In this embodiment, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist and is not a bFGF or EGF polypeptide. The bacterial collagen-binding polypeptide segment delivers the therapeutic agent to sites of partially untwisted or under-twisted collagen.
In addition, methods of treating collagenopathies, such as osteogenesis imperfecta (OI), by administering a composition comprising a bacterial collagen-binding polypeptide segment linked to a PTH/PTHrP receptor agonist to a subject in need of treatment for a collagenopathy are provided. Collagenopathies include but are not limited to osteogenesis imperfecta, Stickler's syndrome, Ehlers-Danlos syndrome, Alport's syndrome, Caffey's disease, and localized collagen or cartilage damage. Many of these diseases are caused by genetic defects that result in the collagen in certain tissues being under twisted or partially untwisted.
For example, individuals with OI carry a mutation which causes an amino acid change in collagen changing a glycine to a bulkier amino acid which results in disruption of the triple helix structure of the collagen and under-twisting of the collagen. In the Examples, we demonstrate that the bacterial collagen-binding polypeptides described herein target and bind to these areas of under-twisted collagen. Thus, use of the collagen-binding polypeptides described herein to deliver a therapeutic agent capable of treating OI to the sites of under-twisted collagen may allow more effective treatment.
The collagen-binding polypeptide segment and the therapeutic agent may be chemically cross-linked to each other or may be polypeptide portions of a fusion protein. The terms “fusion protein” and “fusion polypeptide” may be used to refer to a single polypeptide comprising two functional segments, e.g., a collagen-binding polypeptide segment and a polypeptide based therapeutic agent, such as PTH/PTHrP receptor agonist polypeptide segment. The fusion proteins may be any size, and the single polypeptide of the fusion protein may exist in a multimeric form in its functional state, e.g., by cysteine disulfide connection of two monomers of the single polypeptide. A polypeptide segment may be a synthetic polypeptide or a naturally occurring polypeptide. Such polypeptides may be a portion of a polypeptide or may comprise one or more mutations. The two polypeptide segments of the fusion proteins can be linked directly or indirectly. For instance, the two segments may be linked directly through, e.g., a peptide bond or chemical cross-linking, or indirectly, through, e.g., a linker segment or linker polypeptide. The peptide linker may be any length and may include traditional or non-traditional amino acids. For example, the peptide linker may be 1-100 amino acids long, suitably it is 5, 10, 15, 20, 25 or more amino acids long such that the collagen binding portion of the fusion polypeptide can mediate collagen binding and the therapeutic agent can have its therapeutic effect. Peptide linkers may include but are not limited to a PKD (polycystic kidney disease) domain from a collagenase or other protein such as in SEQ ID NO: 2, a GST or His-tag, or a Ser or Gly linker.
The collagen-binding polypeptide segment is a polypeptide that binds collagen and may be part of a larger fusion protein, bioactive agent, or pharmaceutical agent. Determination of whether a composition, polypeptide segment, fusion protein, or pharmaceutical or bioactive agent binds collagen can be made as described in U.S. Patent Publication No. 2010/0129341, which is incorporated herein by reference in its entirety. Briefly, it is incubated with collagen in binding buffer, and the mixture is then filtered through a filter that would otherwise allow it to pass through but that blocks the collagen and therefore holds back materials that bind to the collagen. The filtrate is then assayed for the presence of the composition, polypeptide segment, fusion protein, or pharmaceutical or bioactive agent. Suitably, at least 80%, 85%, 90%, 95%, 98% or more suitably at least 99% of the collagen-binding composition, polypeptide segment, fusion protein, or pharmaceutical or bioactive agent is retained by the filter in this assay, as compared to when the filtration is performed without collagen.
The collagen-binding polypeptide segment may be a bacterial collagen-binding polypeptide segment. It may be a Clostridium collagen-binding polypeptide segment. The collagen-binding polypeptide segment may be a segment of a collagenase, or a bacterial collagenase, or a Clostridium collagenase. Suitably the polypeptide segment is only a portion of the collagenase and the collagen-binding polypeptide segment does not have collagenase activity. The collagen-binding polypeptide may be a bacterial M9B (including those derived from Bacillus spp. and Clostridium spp.) or M9A (including those derived from Vibrio spp.) collagen-binding protein or a collagen-binding peptide derived from such a protein. By “derived from” we mean that the peptide is a fragment of the full-length protein, a peptide that has amino acid changes relative to the wild-type protein or a combination thereof. The key is that the peptide retains the ability to bind collagen. For example, a peptide may be derived from a protein by selecting a region of the protein capable of binding to collagen. Compositions including a bacterial collagenase as a collagen binding peptide are described in US Patent Publication No. 2010/0129341, which is hereby incorporated herein by reference in its entirety.
In one embodiment, the collagenase is ColH, SEQ ID NO: 6. The collagen-binding polypeptide segment may be or may include residues 901-1021 of SEQ ID NO:6 (residues 34-158 of SEQ ID NO:1), or a fragment of residues 34-158 of SEQ ID NO:1 at least 8, 10, 12, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 110 or 120 amino acid residues in length. The collagen-binding polypeptide segment is at least 50%, 60%, 70%, 80%, or at least 85%, at least 90%, at least 95%, at least 96%, at least 98%, or at least 99% identical to residues 34-158 of SEQ ID NO: 1. The collagen-binding polypeptide segment may be or may include residues 807-1021 of SEQ ID NO:6 (residues 37-251 of SEQ ID NO:2), or a fragment of residues 807-1021 of SEQ ID NO:6 at least 8, 10, 12, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 110 or 120 amino acid residues in length. Residues 807-901 comprise the polycystic kidney disease (PKD) domain of the collagen-binding protein. Those of skill in the art will appreciate that other linkers could be used to link the collagen-binding peptide to a therapeutic agent as outlined above. The collagen-binding polypeptide segment may be or may comprise a fragment of residues 901-1021 of SEQ ID NO:6, e.g., a fragment of at least 8, at least 10, at least 20, at least 30 at least 40, or at least 50 consecutive amino acid residues of residues 901-1021 of SEQ ID NO:6. Suitably the collagen-binding polypeptide consists of residues 894-1008, 894-1021, 901-1021, or 901-1008 of SEQ ID NO: 6 or a homolog thereof as shown by the sequence alignment in
Among other proteins the collagen-binding segment can be derived from are ColG (Matsushita et al., (1999) J. Bacteriol. 181:923-933), a class I collagenase from Clostridium histolyticum. ColH is a class II collagenase (Yoshihara et al., (1994) J. Bacteriol. 176: 6489-6496). The collagen-binding polypeptide segment may also be a polypeptide segment from any one of the protein sequences provided in
The therapeutic agents linked to the collagen-binding polypeptide may be any suitable pharmaceutical or other active agent, including but not limited to, osteogenic promoters, antimicrobials, anti-inflammatory agents, polypeptides such as recombinant proteins, cytokines or antibodies, small molecule chemicals or any combination thereof. Suitably the therapeutic agents are capable of promoting bone growth, decreasing inflammation, promoting collagen stability. Suitably, the therapeutic agent is one whose therapeutic effect is in the region of collagen or damaged collagen. The therapeutic agent may include, but is not limited to, bone morphogenic protein (BMP), G-CSF, FGF, BMP-2, BMP-3, FGF-2, FGF-4, anti-sclerostin antibody, growth hormone, IGF-1, VEGF, TGF-β, KGF, FGF-10, TGF-α, TGF-β1, TGF-β receptor, CT, GH, GM-CSF, EGF, PDGF, celiprolol, activins and connective tissue growth factors. In alternative embodiments, the active agent may be a PTH/PTHrP receptor agonist or antagonist.
Bone loss due to a collagenopathy such as osteogenesis imperfecta, Stickler's syndrome or others which put an individual at higher risk for a bone fracture due to a collagen defect could be treated by administration of a bone anabolic peptide. The CBD may target the bone anabolic agents to sites where the collagen is malformed and thus may prevent fracture.
Vascular fragility due to defects such as Ehlers-Danlos syndrome type IV, Alport's syndrome or other diseases where blood vessel rupture is more likely due to a defect in collagen formation may be administered peptides that stimulate vascular growth or repair. The CBD will target the peptide to the areas having collagen damage and these areas are likely to have damaged vessels. The therapeutic agents will stimulate growth and repair at the site of damage and prevent vessel rupture.
Skin fragility due to disorders such as Ehlers-Danlos syndrome, Caffey's disease or other diseases where weakening of the skin due to a collagen defect leads to hyperelasticity, easy bruising or poor wound healing. Dermal and epidermal growth factors may serve as therapeutic agents which when linked to CBD and delivered to areas of damaged collagen will stimulate growth and repair of the skin, preventin striae and improving healing.
Collagen defects may also lead to cartilage malformation or insufficiency. Cartilage growth factors could be delivered locally to sites of damaged cartilage to aid in repair and restore function.
The PTH/PTHrP receptor agonist polypeptide segment may be a synthetic polypeptide or a naturally occurring polypeptide. Such polypeptides may be a portion of a polypeptide or may comprise one or more mutations. The mutations may make the PTH/PTHrP receptor agonist a better or worse agonist as compared to the wild-type PTH/PTHrP. Agonist activity with the PTH/PTHrP receptor can be assayed as described in Example 3 below by a cAMP stimulation assay. An agonist will stimulate cAMP synthesis in the assay described. Suitably, an agonist can activate receptor activity at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or even 110% or 120% as much as wild-type PTH(1-34).
The PTH/PTHrP receptor agonist polypeptide segment is a PTH or PTHrP polypeptide segment. One human isoform of PTH is SEQ ID NO:7. One human isoform of PTHrP is SEQ ID NO:8. While the human isoforms are provided, those of skill in the art will appreciate that other non-human-derived isoforms may be used as well. Such non-human-derived isoforms may be able to interact with human PTH/PTHrP receptor and vice versa. The PTH/PTHrP receptor agonist polypeptide segment may be or may include residues 1-33 of SEQ ID NO:1 (residues 1-33 of PTH (SEQ ID NO:7)). The PTH/PTHrP receptor agonist polypeptide segment may be or may include residues 1-34 of PTH (SEQ ID NO:7). In other embodiments, it is a fragment of residues 1-34 of PTH (SEQ ID NO:7). In other embodiments, the PTH/PTHrP receptor agonist polypeptide segment may be or may include residues 1-84 of PTH (SEQ ID NO:7). In other embodiments, the PTH/PTHrP receptor agonist polypeptide segment may be or may include residues 1-14 of PTH (SEQ ID NO:7). In still other embodiments, the PTH/PTHrP receptor agonist is a PTH or PTHrP polypeptide segment for any other species.
The PTH/PTHrP receptor antagonist can include in one embodiment PTH(7-34), i.e., residues 7-34 of PTH (SEQ ID NO:7). In another embodiment, it is or includes residues 7-33 of PTH (SEQ ID NO:7). In other embodiments, it is a fragment of residues 7-34 of SEQ ID NO: 8. In another embodiment, the PTH/PTHrP receptor antagonist includes PTH(7-14), i.e., residues 7-14 of PTH (SEQ ID NO:7). In another embodiment, the PTH/PTHrP receptor antagonists include ((−1)-33) of PTH/PTHrP. In another embodiment, the PTH/PTHrP receptor antagonists include residues 1-14 of PTH with an N-terminal extension. Adding an N-terminal extension to PTH or active N-terminal fragments of PTH converts the PTH peptides to antagonists. The N-terminal extension can be 1, 2, 3, 4, 5, or more amino acids in length. The identity of the amino acids in the N-terminal extension is typically not important. In one embodiment, the PTH/PTHrP receptor antagonist includes residues 1-33 of PTH with a Gly-Ser extension at the N-terminus (SEQ ID NO:11). In another embodiment, the PTH/PTHrP receptor antagonist includes PTHrP(7-34), i.e., residues 7-34 of SEQ ID NO:8, or a fragment of residues 7-34 of SEQ ID NO:8. In another embodiment, the PTH/PTHrP receptor antagonist includes mouse TIP(7-39) (See Hoare S R, Usdin T B. 2002. Specificity and stability of a new PTH1 receptor antagonist, mouse TIP(7-39). Peptides 23:989-98). Other PTH/PTHrP receptor antagonists that may be used in the fusion proteins are also disclosed in Hoare et al. The PTH/PTHrP receptor antagonist may be a fragment of at least 8, 10, 12 or more amino acids from residues 1-34 of SEQ ID NO:7. In other embodiments the PTH/PTHrP receptor antagonist may be PTH/PTHrP receptor antagonist polypeptide from another species.
In one embodiment, the therapeutic agent or PTH/PTHrP receptor agonist or antagonist polypeptide segment is N terminal to the collagen-binding polypeptide segment in the fusion protein. That is, the two polypeptide segments each have an N-terminal and a C-terminal, and the N-terminal of the collagen-binding polypeptide segment is linked directly or indirectly, e.g., through a linker polypeptide segment (such as PKD, a Glycine or Serine linker) to the C-terminal of the therapeutic agent or PTH/PTHrP agonist or antagonist polypeptide segment.
The fusion proteins described above comprising (a) a collagen-binding polypeptide segment linked to (b) a therapeutic agent or a PTH/PTHrP receptor agonist or antagonist polypeptide segment can be replaced by pharmaceutical agents comprising (a) a collagen-binding polypeptide segment linked to (b) a therapeutic agent or PTH/PTHrP receptor agonist or a non-peptidyl PTH/PTHrP receptor agonist. An example of a non-peptidyl PTH/PTHrP receptor agonist is compound AH3960 (Rickard et al., (2007) Bone 39:1361-1372).
AH3960 contains two amino groups. Amino groups in small chemical molecules such as AH3960 can be used to cross-link the therapeutic agent to amino groups on the collagen-binding polypeptide segment through a cross-linker such as DSG (disuccinimidyl glutarate) or through the combination of SANH (succinimidyl-4-hydrazinonicotinate acetone hydrazone) and SFB (succinimidyl-4-formyl benzoate). Therapeutic agents can be cross-linked through their amino group to a carboxyl group of the collagen-binding polypeptide segment by EDC (1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride) or vice versa. These cross-linking products are available from Pierce (piercenet.com, Thermo Fisher Scientific Inc., Rockford, Ill.). Protocols and reaction conditions are also available in the product literature from Pierce (piercenet.com).
In another embodiment of the pharmaceutical agents comprising (a) a collagen-binding polypeptide segment; linked to (b) a polypeptide therapeutic agent or a PTH/PTHrP receptor agonist or antagonist polypeptide segment, segment (a) and segment (b) are separate polypeptides, and the two polypeptides are linked by chemical cross-linking. The two polypeptides can be cross-linked through amino groups by reagents including DSG (disuccinimidyl glutarate) or glutaraldehyde. They can also be cross-linked through amino groups by derivatizing one polypeptide with SANH (succinimidyl-4-hydrazinonicotinate acetone hydrazone) and the other with SFB (succinimidyl-4-formyl benzoate), and then mixing the two derivatized polypeptides to cross-link. The two polypeptides can be cross-linked between an amino group of one polypeptide and a carboxyl of the other by reaction with EDC (1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride). The polypeptides can also be cross-linked (e.g., covalently coupled) by any other suitable method known to a person of ordinary skill in the art. These cross-linking reagents are available from Pierce (piercenet.com, Thermo Fisher Scientific Inc., Rockford, Ill.). Protocols and reaction conditions are also available in the product literature from Pierce (piercenet.com). These and other applicable cross-linking methods are described in U.S. published patent applications 2006/0258569 and 2007/0224119.
Also provided herein are methods of treating hyperparathyroidism by administering PTH-CBD to a subject in need of treatment for hyperparathyroidism. In one embodiment the PTH administered to the subject may be a PTH from a different species. As shown in the Examples a single administration of CBD-PTH to ovarectomized aged rats was able to reduce the amount of endogenous PTH produced by the animal. Thus, administration of PTH-CBD to individuals suffering from hyperparathyroidism may experience a decrease in symptoms associated with hyperparathyroidism and have decreased levels of PTH after administration of PTH-CBD.
The effects of PTH agonists and antagonists on hair growth have been studied for over almost 15 years. PTH has a common receptor with PTH-related peptide (PTHrP), which is normally produced by dermal fibroblasts. PTHrP affects keratinocyte proliferation/differentiation and modulates the hair cycle. Most of the testing on hair growth effects has been performed with PTH antagonists, as indications from initial testing were that these were the most effective agents. Both injected and topical formulations have been tested in animal models of chemotherapy-induced alopecia and in the SKH-1 hairless mouse. Part of the effect of PTH antagonists on hair growth is to transition the hair follicles into a dystrophic catagen stage, which protects them from chemotherapeutic damage. However, clinical trials of topical PTH antagonists for chemotherapy-induced alopecia by IGI Pharmaceuticals were discontinued in phase 2 because of limited efficacy. Thus new compositions for treating alopecia are needed.
The problems of delivery and retention of PTH to the skin can be overcome by using collagen-targeted PTH analogs. To accomplish this, we synthesized several fusion proteins of different PTH agonists and antagonists linked to a collagen binding domain derived from the ColH1 collagenase of Clostridium histolyticum. In the studies described in the Examples, we found that the agonist compound PTH-CBD promotes transition of hair follicles to the anagen phase and has potent effects on hair growth. The antagonist compound PTH(7-33)-CBD had little effect on hair growth in chemotherapy models and had a deleterious effect on hair regrowth after depilation. Compounds such as PTH-CBD, which promote anagen phase transition of hair follicles, have been sought after due to their potential to treat a large variety of disorders of hair loss. PTH-CBD appears to have a similar mechanism of action to cyclosporine, which also promotes transition of hair follicles to anagen phase, although the mechanism is less likely to be the result of direct effects on WNT signaling. While clinical use of cyclosporine for this purpose is limited by systemic toxicity, PTH-CBD has not shown toxic effects, even with systemic administration.
Thus in another aspect, methods of increasing hair growth are provided herein. The methods include administering a CBD linked to a PTH/PTHrP receptor agonist to a subject in need of treatment to induce hair growth or stop hair loss. The method is applicable to individuals with alopecia, including chemotherapy induced alopecia, but also alopecia areata, alopecia caused by male pattern baldness, polycystic ovarian syndrome or other hair loss. The compositions may be administered locally or topically to treat hair loss.
In another aspect, methods of slowing hair growth or regrowth after a hair removal procedure by administering a CBD linked to a PTH/PTHrP receptor antagonist to a subject are provided. In one embodiment, the PTH antagonist composition is applied locally, topically. The PTH antagonist may be applied after a hair removal procedure to prevent or slow hair regrowth. As described in the Examples, we have demonstrated that hair regrowth is slowed after waxing in animals treated with CBD-PTH antagonist as compared to control animals treated with PTH-CBD or vehicle alone. The compositions may be administered locally or topically to block hair growth.
The compositions described herein may be administered by any means known to those skilled in the art, including, but not limited to, oral, topical, intranasal, intraperitoneal, parenteral, intravenous, intramuscular, intradermal or subcutaneous. Thus the compositions may be formulated as an ingestable, injectable, topical or suppository formulation. The composition may be formulated for administration by injection to result in systemic administration or local administration. The compositions may also be delivered with in a liposomal or time-release vehicle. The compositions may also be delivered in a site-directed delivery vehicle, such as but not limited to, a targeted liposome or an absorbable collagen sponge carrier or other implant.
The inventors have found that when administering compositions including a CBD subcutaneously it binds locally at the site of injection if the composition is dissolved in neutral pH buffer. But if the composition is dissolved in a low pH buffer, for example a buffer having pH 5.0 or pH 4.5 or below, the collagen-binding domain does not bind collagen, and the composition has time to disperse systemically before it binds collagen elsewhere in the body at neutral pH. Thus systemic administration of the compositions involves administering the composition dissolved in buffer or aqueous solution at a pH lower than about 5.0 or at pH 4.5 or below. In another embodiment, systemic administration of the compositions involves administering the fusion proteins dissolved in aqueous solution at pH lower than about 6.0. Alternatively, if the skin condition is localized, the compositions described herein may be administered in a buffer with a pH of 6.0, 6.5, 7.0, 7.5 or above in order to allow for localized delivery of the compositions to the affected area of the skin.
Pharmaceutical compositions for topical administration may also be formulated using methods and compositions such as those available to those skilled in the art. For example, gels, creams or liposome preparations may be suitable for topical delivery. These delivery vehicles may be formulated to mediate delivery to the lower layers of the skin or to allow for extended release of the pharmaceutical at the site of application.
The compositions can be administered as a single dose or as divided doses. For example, the composition may be administered two or more times separated by 4 hours, 6 hours, 8 hours, 12 hours, a day, two days, three days, four days, one week, two weeks, or by three or more weeks. Optionally, such treatment may be repeated, for example, every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, 4, and 5 weeks or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. The composition is expected to be more effective than a comparable or control composition comprising the therapeutic agent or a PTH/PTHrP receptor agonist that is not linked to a collagen-binding protein. In one embodiment, a smaller amount of the composition may be used or the composition may be administered less frequently than a comparable composition comprising the therapeutic agent or a PTH/PTHrP receptor agonist which is not linked to a collagen-binding protein.
The dosage amounts and frequencies of administration provided herein are encompassed by the terms therapeutically effective and prophylactically effective. The individual doses of pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a therapeutic agent may be approximately the same on a molar basis as doses used for the therapeutic agent alone. It is expected that the pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a therapeutic agent may be administered less frequently, because linking the agent to the collagen-binding polypeptide segment gives it much more prolonged activity in vivo.
Administration of the compositions to a subject in accordance with the invention appears to exhibit beneficial effects in a dose-dependent manner. Thus, within broad limits, administration of larger quantities of the compositions is expected to achieve increased beneficial biological effects than administration of a smaller amount. Moreover, efficacy is also contemplated at dosages below the level at which toxicity is seen.
It will be appreciated that the specific dosage administered in any given case will be adjusted in accordance with the compositions being administered, the disease to be treated or inhibited, the condition of the subject, and other relevant medical factors that may modify the activity of the agent or the response of the subject, as is well known by those skilled in the art. For example, the specific dose for a particular subject depends on age, body weight, general state of health, diet, the timing and mode of administration, the rate of excretion, medicaments used in combination and the severity of the particular disorder to which the therapy is applied. Dosages for a given patient can be determined using conventional considerations, e.g., by customary comparison of the differential activities of the compositions of the invention and of the therapeutic agent administered alone, such as by means of an appropriate conventional pharmacological or prophylactic protocol.
The maximal dosage for a subject is the highest dosage that does not cause undesirable or intolerable side effects. The number of variables in regard to an individual prophylactic or treatment regimen is large, and a considerable range of doses is expected. The route of administration will also impact the dosage requirements. It is anticipated that dosages of the compositions will reduce symptoms of the condition being treated by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% compared to pre-treatment symptoms or symptoms is left untreated. It is specifically contemplated that pharmaceutical preparations and compositions may palliate or alleviate symptoms of the disease without providing a cure, or, in some embodiments, may be used to cure the disease or disorder.
Suitable effective dosage amounts for administering the compositions may be determined by those of skill in the art, but typically range from about 1 microgram to about 10,000 micrograms per kilogram of body weight weekly, although they are typically about 1,000 micrograms or less per kilogram of body weight weekly. In some embodiments, the effective dosage amount ranges from about 10 to about 10,000 micrograms per kilogram of body weight weekly. In another embodiment, the effective dosage amount ranges from about 50 to about 5,000 micrograms per kilogram of body weight weekly. In another embodiment, the effective dosage amount ranges from about 75 to about 1,000 micrograms per kilogram of body weight weekly. The effective dosage amounts described herein refer to total amounts administered, that is, if more than one compound is administered, the effective dosage amounts correspond to the total amount administered.
The effectiveness of the compositions described herein may be enhanced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% relative to a control treated with the therapeutic agent alone. It will be appreciated that the effectiveness of the treatment in any given case will be enhanced variably in accordance with the specific compositions used, the type of disease being treated, the condition of the subject, the specific formulations of the compounds and other relevant medical factors that may modify the activity of the compositions or the responses of the subject as is appreciated by those of skill in the art.
The following examples are meant only to be illustrative and are not meant as limitations on the scope of the invention or of the appended claims. All references cited herein are hereby incorporated by reference in their entireties.
Clostridium histolyticum collagenase causes extensive degradation of collagen in the connective tissue resulting in gas gangrene. The C-terminal collagen-binding domain (CBD) of these enzymes is the minimal segment required to bind to the collagen fibril. CBD binds unidirectionally to the partially untwisted C-terminus of triple helical collagen. Whether CBD could also target under-twisted regions even in the middle of the collagen triple helix was examined. Partially untwisted collageneous peptides were synthesized by introducing a Gly→Ala substitutions into the collagen ([(POG)xPOA(POG)y]3 where x+y=9 and x>3). 1H-15N heteronuclear single quantum coherence nuclear magnetic resonance (HSQC NMR) titration studies with 15N-labeled CBD demonstrated that the untwisted mini-collagen binds to a 10 Å wide 25 Å long cleft. Six untwisted collagenous peptides each labeled with a nitroxide radical were then titrated with 15N-labeled CBD. The paramagnetic nuclear spin relaxation effects showed that CBD binds close to either the Gly→Ala substitution site or to the C-terminus of each mini-collagen. Small angle X-ray scattering (SAXS) measurements revealed that CBD prefers to bind the Gly→Ala site rather than the C-terminus. The HSQC NMR spectra of 15N-labeled mini-collagen and untwisted mini-collagen were unaffected by the titration of unlabeled CBD. The results imply that CBD binds to the partially unwound region of the mini-collagen but does not actively unwind the triple helix.
15N-labeled protein production: The s3b (Gly893-Lys1008) peptide derived from Clostridium histolyticum class I collagenase (ColG) was expressed as a glutathione S-transferase (GST)-fusion protein. The GST-tag was cleaved off by thrombin, and CBD was purified as described previously. Matsushita, et al., (2001) J Biol Chem 276, 8761-8770. Uniform 15N isotope labeling was achieved using Tanaka minimal medium containing 40 mM 15NH4Cl. The labeling efficiency was estimated to be 99.6% by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF-MS).
Peptides: (POG)10 (SEQ ID NO: 35) was purchased from Peptide Institute, Inc. (Osaka, Japan). Other peptides were constructed by a standard N-(9-fluorenyl) methoxycarbonyl (Fmoc)-based strategy on Rink-amide resins (Novabiochem, Darmstadt, Germany). N-terminal spin-labeling was performed on the resin by the treatment with 5 equivalents of 3-carboxy-PROXYL (Aldrich), 1-hydroxybenzotriazole, diisopropylcarbodiimide in N,N-dimethylformamide at room temperature for 2 hours. Peptide cleavage and de-protection steps were performed by a treatment with a standard trifluoroacetic acid (TFA) scavenger cocktail (TFA: m-cresol:thioanisole:water:triisopropylsilane=82.5:5:5:5:2.5, v/v). The spin-labeling at Cys residues was performed using 3-(2-iodoacetamido)-PROXYL (IPSL, Sigma-Aldrich). Briefly, 10 molar excess of IPSL dissolved in ethanol was added to the same volume of 10 mg/ml peptide in 0.1 M Tris-HCl (pH 8.8), 5 mM ethylenediaminetetraacetic acid. After reacting at room temperature for 1 hr, the reaction was quenched by adding excess dithiothreitol. All peptides were purified by reverse-phase HPLC using a Cosmosil 5C18 AR-II column (Nacalai Tesque, Kyoto, Japan) and characterized by MALDI-TOF-MS. All the measured masses agreed with the expected values. The chemical structures of synthesized peptides are shown in
Circular dichroism spectroscopy: The triple helical conformation and the stability of the collagenous peptides were verified using CD spectroscopy (See
NMR spectroscopy: NMR experiments were performed on a Bruker 700 MHz spectrometer equipped with Cryoprobe™. All the NMR titration experiments were carried out at 16±0.5° C. The working temperature is lower than the melting temperatures (TM) of all the paramagnetic spin-labeled collagenous peptides (Table 1) used. The concentration of the protein was 0.1 mM in 50 mM Tris-HCl (pH 7.5) containing 100 mM NaCl and 20 mM CaCl2. The dilution effect on the course of titration was minimized by the titration of a highly concentrated (4 mM) peptide stock. Aliquots of collagenous peptide were added to the protein and equilibrated for 5 min before acquiring 1H-15N HSQC spectra. The pH of the NMR samples monitored during the titration exhibited no significant shift in the pH (within ±0.2 units).
11PROXYL-(POG)3PCG(POG)4
Dynamic light scattering experiments: The dynamic light scattering (DLS) data were collected using DynaPro-E equipped with a temperature controlled microsampler on the samples of CBD, collagenous peptides and CBD:mini-collagen complexes in 10 mM Tris-HCl (pH 7.5) containing 100 mM sodium chloride and 20 mM CaCl2. The protein samples were spun at 10,000 rpm for 10 min and were filtered through 0.02 μm Whatman syringe directly into a 50-μL quartz cuvette. For each experiment, 20 measurements were made. The mean hydrodynamic radius (RH), standard deviation, polydispersity, and percent of peak area were analyzed using Dynamics V6 (Protein Solutions). The hydrodynamic radius and molecular weight estimations were calculated from time dependent fluctuations induced by Brownian motion as described. Proteau, et al. (2010) Curr Protoc Protein Sci Chapter 17, Unit 17 10.
Small angle X-ray solution scattering experiments: The small angle X-ray solution scattering (SAXS) data were collected on solutions of CBD, collagenous peptides and CBD-mini-collagen complexes in 10 mM Tris-HCl (pH 7.5), 100 mM NaCl and 20 mM CaCl2 at SAXS/WAXS setup located at the 5-ID-D beamline of the DND-CAT synchrotron research center, Advanced Photon Source, Argonne National Laboratory (Argonne, Ill.). The main advantage of X-ray scattering is that it can be carried out in solution in near physiological conditions. Petoukhov et al., (2007) Curr Opin Struct Biol 17, 562-571. 1.2398 Å (10 keV) radiation was selected from the APS Undulator A insertion device using a Si-111 monochromator, with 1:1 horizontal focusing and higher harmonic rejection from a Rh coated mirror, and beam defining slits set at 0.3 mm vertical by 0.25 mm horizontal. A 1.6 mm diameter capillary flow-cell with a flow rate of 4 μl/sec was used to collect four frames with 10 second exposure time. The SAXS detector used was a Mar165 scintillator fiber-optic coupled CCD detector and covered the momentum transfer range 0.005<q<0.198 Å−1, where q=4π sin θ/λ (2θ is the scattering angle). The WAXS detector was a custom Roper scintillator fiber-optic coupled CCD detector and covered 0.191<q<1.8 Å−1 S. Weigand, et al. (2009) Advances in X-ray Analysis 52, 58-68.
All scattering data were acquired at sample temperature of 10° C. The four scattering patterns from each detector were averaged and merged with the rejection of outlying scans. For further analysis the program IGOR Pro 5.5 A (WaveMetrics) was used. The scattering profiles of the protein, peptide and their complexes were obtained after subtracting the buffer profiles. The reduced scattering data were plotted as scattering intensity I(Q) vs. Q (
Docking model: The CBD-collagenous peptide complex is generated from Protein Data Bank entries of ColG s3b (1NQD) and partially untwisted collagenous peptide 1CAG (Ala mutation in 15th position). Other untwisted mini collagen molecules were generated by modifying 1CAG using fragments derived from [(POG)10]3 structure (1K6F). To obtain the complex, the soft docking algorithm BiGGER was used. Palma, et al. (2000) Proteins 39, 372-384. Solutions were filtered using NMR titration data and the highest scoring model that satisfied NMR and SAXS results was chosen. The manual adjustments were aided by the use of MIFit. McRee. (1999) J Struct Biol 125, 156-165.
1H-15N HSQC NMR titration-CBD targeting the under-twisted sites in collagen: The untwisted collagenous peptide [(POG)6POA(POG)3]3 (SEQ ID NO: 36) that has Ala in the 21st position from the N-terminus was synthesized. This peptide was further modified to accommodate a paramagnetic spin label at the N-terminus. 1H-15N HSQC NMR titrations were performed with [PROXYL-(POG)6POA(POG)3]3 (SEQ ID NO: 36) and 15N-labeled CBD at ratios ranging from 0.02:1 to 1.5:1. As demonstrated earlier, a total of eleven residues on the collagen binding interface (S928, W956, G971, K995, Y996, L924, T957, Q972, D974, L991 and V993) either disappeared from the HSQC spectrum or exhibited significant chemical shift perturbation from their original position on the course of titration. Philominathan, et al. (2009) J Biol Chem 284, 10868-10876. The PROXYL group on the N-terminus of the collagenous peptides can cause a distance-dependent line broadening of the NMR signals of CBD during the course of titration. In addition to the eleven residues, three more residues, V973, G975 and S979 exhibited appreciable line broadening and these residues eventually disappeared from the 1H-15N HSQC spectrum of CBD (
As paramagnetic relaxation enhancement is a distance dependent phenomenon, Gly→Ala substitution made at closer to the N-terminal PROXYL group should result in the disappearance of more residues on CBD. PROXYL containing collagenous peptides, [PROXYL-(POG)5POA(POG)5POA(POG)4]3 (SEQ ID NO: 37) (Ala at 18th position from the N-terminal PROXYL), [PROXYL-(POG)4POA(POG)5]3 (SEQ ID NO: 38) (Ala at the 15th position from the PROXYL) and [PROXYL-(POG)3POA(POG)6]3 (SEQ ID NO: 39) (Ala at the 12th position from the PROXYL) were synthesized. Just as in the previous titrations, the line broadening effects on the residues of CBD were analyzed from the changes in the 1H-15N HSQC spectrum. The shorter the distance between Gly→Ala substitution site and the N-terminal PROXYL, more residues in CBD disappeared (
The helical conformation in both the [(POG)2POA]3 (SEQ ID NO: 45) and the C-terminal [(POG)3]3 (SEQ ID NO: 44) are similarly under-wound. The degree of rotation about the screw axis symmetry that describes the internal triple helical twist is defined as the helical twist value κ. The κ-value oscillates around an average value of −103° for [(POG)10]3 (SEQ ID NO: 35). Bella (2010) J Struct Biol 170, 377-391. The C-terminus of a mini-collagen is under-twisted (κ value shifts from −103° to −110°) but the N-terminus is usually over-twisted. Collagen peptides with Gly→Ala substitution in the center of the peptide sequence still form triple helices, but with an abrupt under-twisting (κ value shifts from −103° to −115°) at the substitution site followed over-twisting to the norm. Because the [(POG)2POA]3 (SEQ ID NO: 45) region is somewhat more under-twisted than C-terminal [(POG)3]3 (SEQ ID NO: 44), the former could be preferentially targeted by CBD than the latter. However, CBD could still bind to the C-terminus.
CBD also targets the C-terminus of the under-twisted mini-collagen: To demonstrate that CBD binds to the C-terminal (POG)3 (SEQ ID NO: 44) as well, a collagenous peptide [(POG)4POA(POG)5-PROXYL]3 (SEQ ID NO: 38) was synthesized. [(POG)4POA(POG)5C-PROXYL]3 (SEQ ID NO: 41) was titrated with 15N-labeled CBD at ratios 0.02:1 to 1.5:1 with increments of 0.02, and the changes in the HSQC spectrum of CBD were monitored. When the mini-collagen was bound to the cleft, a total of eleven residues on the collagen binding interface either line broadened or showed significant chemical shift perturbation as described earlier. Philominathan, et al. (2009) J Biol Chem 284, 10868-10876. Four additional residues S906, R929, S997 and G998 disappeared from the HSQC spectrum due to PROXYL (
To demonstrate CBD's ability to target both the (POG)2POA (SEQ ID NO: 45) region and the C-terminal (POG)3 (SEQ ID NO: 44) region, a collagenous peptide [11PROXYL-(POG)3PCG(POG)4]3 (SEQ ID NO: 40) modified to accommodate PROXYL group in the middle (11th position) was synthesized. PROXYL group is covalently joined to the cysteine residue. Due to the presence of the bulky PROXYL group, this peptide is expected to be partially untwisted. The precise degree of under-twisting is not known for the peptide, but mini-collagen with GPX repeats exhibits a moderate under-twisting (κ=−105°). Bella. (2010) J Struct Biol 170, 377-391. The bulky PROXYL group will likely induce greater untwisting than κ=−105°. In addition to the eleven amide resonances either line-broaden or shifted, 1H-15N HSQC NMR titrations revealed two distinct phenomena. At lower ratio (0.2:1) amide resonances corresponding to S906, R929, S997, and G998 disappeared from the HSQC spectrum of CBD (
To demonstrate that PROXYL caused the line broadening and Ala or Cys residues did not, three more control peptides, [(POG)4POA(POG)5]3 (SEQ ID NO: 38), [(POG)4POA(POG)5C-carbamidomethyl]3 (SEQ ID NO: 41), and [(POG)3PCG(POG)4]3 (SEQ ID NO: 40) that lack the PROXYL groups were synthesized, and NMR titrations were repeated (
To illustrate if CBD binds only to the partially untwisted site in the middle of the collagen peptide and/or to the C-terminus of mini-collagen, dynamic light scattering experiments (DLS) were performed. DLS experiments provided the stoichiometries of collagen:CBD complexes. The hydrodynamic radius of [(POG)4POA(POG)5-PROXYL]3 (SEQ ID NO: 38):CBD and [11PROXYL-(POG)3PCG(POG)4]3 (SEQ ID NO: 40):CBD was 3 nm and the apparent molecular weight of the complex was 42±1 kDa, which is similar to those observed for [(POG)10]3 (SEQ ID NO: 35):CBD complex (Table 3). Other complexes also exhibited similar values. Thus far, all the mini-collagen and CBD always formed 1:1 complex. CBD binds to either one of the available sites in mini-collagen but does not occupy both sites to form a 1:2 complex.
Small angle X-ray scattering experiments (SAXS): The three dimensional molecular shapes of the CBD-collagenous peptide complexes were constructed using SAXS measurements. The main advantage of SAXS measurements is that the experiments are performed in solution under near physiological conditions. In our previous work, these three dimensional molecular envelopes were used to demonstrate asymmetric binding of CBD to the C-terminal (POG)3 (SEQ ID NO: 44) of mini-collagen. The molecular shapes were constructed for complexes of CBD and six different untwisted mini-collagen molecules. In all cases CBD bound to (POG)2POA (SEQ ID NO: 45) region preferentially to C-terminal (POG)3 (SEQ ID NO: 44) (
Structures derived from SAXS profiles using simulated annealing calculations for [11PROXYL-(POG)3PCG(POG)4]3 (SEQ ID NO: 40) (
Little structural change of 15N-minicollagen upon CBD binding: The studies thus far suggest that CBD scans the collagen fibril for under-twisted regions. Upon binding to the less structured regions, does it actively unwind collagen? Active unwinding by CBD would facilitate collagenolysis. To investigate two collagenous peptides selectively labeled with 15N near N- or near C-terminus of [(POG)10]3 (SEQ ID NO: 35) were synthesized (Table 4, peptides A,B), and the structural changes due to the binding of unlabeled CBD were monitored using 1H-15N HSQC titration.
15N-Labeled Mini-collagen
The 15N-Gly labeled peptides exhibited two distinct cross peaks in the 1H-15N HSQC spectrum (
Untwisted mini-collagen molecule selectively labeled with 15N-Gly either at near the N- or C-termini (Table 4C and D) was titrated with unlabeled CBD. Cross peaks corresponding to monomer and triple-helix were identified on the HSQC spectra (
CBD unidirectionally binds to the under-twisted site in the triple helical collagen. CBD may help disband the collagen fibril, but does not unwind the triple helix. Targeting under-twisted regions of tropocollagen may circumvent the energy barrier required for unwinding the triple helices. When CBD is used as a drug delivery molecule, the injected molecule distributes prominently to the end plates of vertebral discs, near the growth plates of tibia and fibula, and also to skin. It could be unloading its payload to the most blood accessible collagen that is undergoing remodeling, thus rich in under-twisted regions.
The C-terminal collagen-binding domain (CBD) of collagenase is required for insoluble collagen fibril binding and for subsequent collagenolysis. The high resolution crystal structures of ColG-CBD (s3b) and ColH-CBD (s3) the molecules resemble one another closely (r.m.s.d. Cα=1.5 Å), despite sharing only 30% sequence identity. Five out of six residues chelating Ca2+ are conserved. The dual Ca2+ binding sites in s3 are completed by a functionally equivalent aspartate. The three most critical residues for collagen interaction in s3b are conserved in s3. The general shape of the binding pocket is retained by altered loop structures and side-chain positions. Small angle X-ray scattering data revealed that s3 also binds asymmetrically to mini-collagen. Besides the calcium-binding sites and the collagen-binding pocket, architecturally important hydrophobic residues and hydrogen-bonding network around the cis-peptide bond are well-conserved in metallopeptidase subfamily M9B.
Common structural features described above and in Bauer et al. (2012) J Bacteriol November 9 (which is incorporated herein by reference in its entirety), enabled us to update the sequence alignment of the CBD in the M9B subfamily (
The dual calcium-binding site is formed by four chelating residues (Glu899, Glu901, Asn903, and Asp904) within the N-terminal linker, two chelating residues (Asp927 and Asp930) from the β-strand C and invariant Tyr1002 hydrogen-bonds and orients Asp930. Residue numbers used in this paragraph are of s3b. Likewise other supporting cast such as Gly921 is conserved in the middle of β-strand strategically placed to make room for Glu899. The dual calcium chelation site is fashioned sometimes by functionally equivalent residues. As mentioned, Asp897 of s3 acts equivalently to Asp927 of s3b. Asp897 equivalents are tentatively identified in B. brevis s3a and s3b, C. botulinum A3 s3a and C. histolyticum ColG s3a. Tridentate and divalent Asp and Glu residues are conserved with only C. sordellii s3a as the exception. The monodentate Asp904 residue is sometimes substituted by Asn. For those substituted, the net charge of the dual calcium site is neutral rather than −1.
The peptide between residues 901-902 has cis conformation in the holo state for both s3b and s3. The position 902 in other CBD molecules is Pro, Asp or Asn. Pro frequently succeeds the peptide bond to ease trans-cis isomerization. The s3 molecule has Pro. In s3b, OD of Asn902 hydrogen-bonds with the main-chain N of Asp904. The hydrogen-bond is critical for the peptide isomerization. Spiriti and van der Vaart. (2010) Biochemistry 49:5314-5320, which is incorporated herein by reference in its entirety. For the remainder of CBD molecules with Asp at the position, OD of Asp could play the same role as that of Asn902. Other hydrogen-bonds identified by simulation studies important in stabilizing the transition states are well conserved. These donor-acceptor pairs in s3 and s3b are tabulated (Table 5). Calcium ions could catalyze the isomerization in all the CBD molecules and their transition states and catalytic mechanism may look very similar.
Non-functional residues that are important in either folding or architectural stability are conserved. Hydrophobic residues packed between the β-sheets are better conserved if they are located in the vicinity of functionally critical residues. For example, invariant Trp956 of strand E is packed between the β-sheets. The residues flanking (Thr955 & Thr957) interact with mini-collagen. Tyr932 is packed between the sheets and helps positioning Tyr1002. Residues at tight turns are conserved as well. Gly975 is well conserved to allow a type II′ turn in s3b. Gly942 (Gly975 equivalent) in s3 allows Asp941 side-chain to stabilize the reverse turn. A highly conserved six-residue stretch, between residues 986 and 991, adopts a tight turn and precedes the functionally important strand H. The region is well ordered in the crystal structures with low B-factors, and is the least dynamic based on NMR and limited proteolysis MALDI-TOF MS (25). Philominathan, et al. (2009) J Biol Chem 284:10868-10876 and Sides et al. J Am Soc Mass Spectrom. (2012) 23(3):505-19 both of which are incorporated herein by reference in their entireties. The main-chain carbonyl and amino groups of Arg985 hydrogen-bond with OH of Tyr989 to stabilize the turn. Only Gly987 can make room for the bulky Tyr989 side chain. Tyr990 packs against the invariant Ala909 and conserved 310 helix.Ala909 is at the base of the linker that undergoes α-helix→β-strand transformation. The tight turn may ensure that collagen interacting Leu992, Tyr994, and Tyr996 would be correctly positioned. Tyr994 is the most critical residue in interacting with collagenous peptides. Wilson, et al. (2003) EMBO J 22:1743-1752. The strands adjacent to strand H, i.e. strands C and E, are very well conserved. The three antiparallel strands mold the collagen-binding pocket. Strand F staples the β-sheets by interacting with both sheets. The β-strand first interacts in an antiparallel orientation with strand E then breaks its direction at Gly971 to interact with strand G. In place of Gly971, Ala or Pro is found at the location where the strand switches its allegiance. The dual interaction of the strand helps positioning Tyr970 to interact with mini-collagen.
Three residues shown to interact strongly with mini-collagen are conserved. The invariant Tyr994 and well conserved Tyr970 and Tyr996 constitute the “hot spot”. Y994A mutation lost binding capability. Since Y994F resulted in 12-fold reduction in binding to mini-collagen, the hydroxyl group of Tyr994 may interact with collagen through a hydrogen-bond. Tyr996, which is a critical residue in binding mini-collagen, is not so well conserved. Y996A caused 40-fold reduction in binding to the mini-collagen. Y996 is s3b is replaced with Phe in s3, though both side chains have identical orientation. In other CBD molecules, an aromatic residue, such as Phe or His, is sometimes found at the site. Y970A results in 12-fold reduction in binding to mini-collagen. Thr957 was found to interact with mini-collagen by 15N-HSQC-NMR titration. The β-branched amino acid residues or Leu are found at the positions equivalent to Thr957 in most of the CBDs. Six other residues were identified by 15N-HSQC-NMR titration to interact with mini-collagen are not very well conserved. Since divergent CBDs (s3 and s3b) adopted a similar saddle-shaped binding pocket, other CBDs may also adopt similar collagen-binding strategy.
Divergent CBD could target different collagen sequences and could possibly target different collagen types; however, this structural study suggest otherwise. Rather, all the CBD domains may bind similarly to an under-twisted region such as the C-terminus of a collagen fibril. The C-terminus of type I collagen is exposed in the fibril surface based on X-ray fiber diffraction experiments, and it is the most accessible site for the bacterial collagenase to initiate assaults. However CBD binding only at the C-terminal region of tropocollagen is unfounded. Gold particle-labeled tandem ColG-CBD (s3a-s3b) labeled with gold particle bound to type I collagen fibrils exhibited no periodicity. In the collagen fibrils, the molecules are staggered from each other by about 67 nm. Therefore CBD could target partially under-twisted regions in the middle of a tropocollagen that are also vulnerable for assaults.
Much like s3b, s3 is both compact, and extremely stable in the presence of physiological Ca2+. Thus, the enzyme could degrade extracellular matrix for prolonged time. The linker that induced structural transformation is a common feature found in M9B collagenase. It could act as Ca2+ sensor to trigger domain rearrangement as means of enzyme activation. Ca2+ concentration in extracellular matrix is higher than that inside a bacterium. Both s3 and s3b bind similarly to a mini-collagen, thus M9B collagenase molecules could initiate collagenolysis from analogous structural features in various collagen fibril. Fusion protein of any CBD derived from M9B collagenase and a growth factor should result in comparable clinical outcome.
In-Vitro Characterization of CBD-Linked PTH Compounds: Collagen binding of each peptide was verified in flow-through collagen binding assays as previously described in U.S. Patent Publication No. 2010/0129341, which is incorporated herein by reference in its entirety. PTH-CBD, consisting of the first 33 amino acids of PTH linked directly to the collagen binding domain (SEQ ID NO: 1), was the most potent agonist, having a similar effect to that of PTH(1-34) (SEQ ID NO: 7) on cAMP accumulation. Ponnapakkam et al. (2011) Calcif 88:511-520. Epub 2011 April 2022. Among the antagonists, PTH(7-33)-CBD (SEQ ID NO: 10) had the best combination of low intrinsic activity and high receptor blockade (not shown), similar to those seen in other PTH antagonists, including those used in hair growth studies. Peters, et al. (2001) J Invest Dermatol 117:173-178.
In-Vivo Distribution of PTH-CBD: Tissue distribution was assessed by administering 35S-labelled PTH-CBD via subcutaneous injection, followed by whole mount frozen and whole-body autoradiography. PTH-CBD with a phosphorylation site between PTH(1-33) and the CBD was purified, activated and labeled with [gamma-35] ATP as described previously. Tamai et al. (2003) Infect Immun. 71:5371-5375. Approximately 10.8 mcg of 35S-PTH-CBD (122 kcm/mcg) was injected subcutaneously in 7 week-old mice (32-35 g). Mice were sacrificed at 1 hour or 12 hours post-injection, and then frozen in dry ice-acetone. Frozen sections (50 μm) were prepared with an autocryotome, dried at −20° C., and exposed to an image plate for 4 weeks. There appeared to be an initial distribution of 35S-PTH-CBD to a broad area of skin around the site of injection, followed by a rapid redistribution to the skin of the entire animal, as well as to several other tissues (i.e. bone, intestine, bladder) (
PTH-CBD Reverses Hair Loss in Chemotherapy-induced Alopecia in Mice: We compared efficacy of CBD linked PTH agonists and antagonists in chemotherapy-induced alopecia, utilizing an experimental design published by Peters, et al., for non-CBD linked PTH compounds. Peters, et al. (2001) J Invest Dermatol 117:173-178. C57BL/6J mice (Jackson Laboratories, Bar Harbor, Me.) were depilated to synchronize the hair follicles, and cyclophosphamide (CYP, 150 mg/kg) was administered on day 9 to maximize the chemotherapy-induced damage. The agonist (PTH-CBD) and the antagonist (PTH(7-33)-CBD) were administered 2 days prior to chemotherapy, and given the long-term retention of the compounds in the skin, we administered only a single dose to cover the timing of the multiple injections of PTH agonist and antagonist in the study by Peters, et. al. The administered dose of CBD-linked compounds (320 mcg/kg) is well tolerated in mice. Ponnapakkam et al. (2011) Calcif 88:511-520. Epub 2011 April 2022.
The results of the photodocumentation record indicate that the agonist, PTH-CBD, was far more effective at stimulating hair growth than was the antagonist (
Importantly, we saw no evidence of adverse effects from PTH-CBD administration. While PTH injections are known to elevate blood calcium and can cause kidney stones, PTH-CBD had no effect on serum calcium. In addition, there was no evidence of excess hair length on the body or of excess hair growth on the ears and tail, where a full coat is normally not present. The effects of PTH-CBD on hair growth have been confirmed in models of chemotherapy-induced alopecia without depilation, which more closely mimic clinical protocols.
Quantification of Effects of PTH-CBD in Chemotherapy-induced Alopecia: We followed these studies by comparing the effects of different doses of PTH-CBD in chemotherapy-induced alopecia. In these studies, we applied the injections more distally on the back and applied a gray-scale analysis to quantify the amount of hair growth. Injecting more distally in the back allows us to compare regrowth of hair after PTH-CBD treatment with less interference from the normal hair regrowth, which normally proceeds from head to tail in mice. The results are shown in
Chemotherapy-induced Alopecia without Depilation: While the depilated model of chemotherapy-induced alopecia provides a uniform model for comparison of drug effects, the depilation process is known to cause hair follicle injury, and may alter the response of the animals to the PTH-CBD administration. We therefore tested the effects of PTH-CBD in another model of chemotherapy-induced alopecia, where the animals were given 3 courses of cyclophosphamide therapy (50 mg/kg/wk), similar to the usual manner in which cancer patients might be treated. In this model, it takes much longer (4-6 months) for alopecia to develop. Animals that received a single dose of PTH-CBD (320 mcg/kg subcutaneous) prior to the first cycle did not develop hair loss as shown in
In a second study, we compared the effects of PTH-CBD when given prophylactically, at the time of the first cycle of chemotherapy, vs. therapeutically, after the hair loss had developed. While PTH-CBD was effective in both instances, the effects were more prominent when given prophylactically. This is evident both visually and quantitatively in
Depilation Alopecia: The agonist PTH-CBD appears to increase hair growth by increasing the number of anagen phase hair follicles. As such, there is no reason to believe that hair growth effects should be limited to the chemotherapy model. We therefore tested both PTH-CBD and antagonist compound, PTH(7-33)-CBD, after removing hair from C57/BL6J mice by waxing (
PTH-CBD is a fusion protein of the first 33 amino acids of parathyroid hormone (PTH) and a bacterial collagen binding domain. The collagen binding activity causes PTH-CBD to be retained at its site of action in the dermal collagen, maximizing efficacy and reducing systemic side-effects. PTH-CBD stimulates hair growth by causing hair follicles to enter an anagen VI or growth phase, presumably by activating WNT signaling and increasing production of beta-catenin. We therefore plan to conduct the following additional studies to confirm this mechanism of action and to determine the effect of PTH-CBD in two distinct genetic mouse models with WNT signaling inhibition. These data will be used in formulating clinical trials for PTH-CBD as a therapy for alopecia.
Alopecia Areata: Alopecia Areata is a disease of patchy hair loss due to autoimmune destruction of the hair follicles. We tested the efficacy of PTH-CBD in promoting regrowth of hair in an animal model of alopecia areata, the engrafted C3H/Hej mouse. In this model, hair loss develops variably over the first 2 months of life. Shown in
In this experiment, rats had their ovaries surgically removed at age 3 months. At age 9 months, rats were injected with either a single dose of PTH-CBD (320 mcg/kg) or vehicle control. Animals were sacrificed 6 months after therapy (age 15 months). Human intact PTH levels were measured to assess serum levels of PTH-CBD, and were found to be undetectable in both groups. Serum calcium was measured and there were no differences between groups (Vehicle: 13.5+/−1.1 vs. PTH-CBD: 14.3+/−1.1 mg/dl, NS). Rat intact PTH levels were measured to assess endogenous PTH production, and PTH-CBD suppressed the normal increase in endogenous PTH levels seen in aged, ovarectomized rats. These findings indicate that a single injection of PTH-CBD can provide long-term suppression of endogenous PTH production, preventing the normal rise seen with age in the ovarectomized rat model, and thus may serve as a therapy for hyperparathyroidism.
This patent application is a continuation application of U.S. application Ser. No. 15/407,589, filed Jan. 17, 2017 which is a divisional application of U.S. application Ser. No. 14/365,226, filed Jun. 13, 2014, which is a national stage filing under 35 U.S.C. 371 of International Application No. PCT/US2012/069831, filed Dec. 14, 2012, which claims the benefit of priority of U.S. Provisional Patent Application No. 61/570,620, filed Dec. 14, 2011 and of U.S. Provisional Patent Application No. 61/596,869, filed Feb. 9, 2012, all of which are incorporated herein by reference in their entireties. This patent application is a also a divisional application of U.S. application Ser. No. 15/386,626 filed Dec. 21, 2016 and issuing on Feb. 26, 2019 as U.S. Pat. No. 10,213,488, which application is a division of U.S. patent application Ser. No. 14/378,067 filed Aug. 11, 2014 (U.S. Pat. No. 9,526,765, issued Dec. 27, 2016), which application is a national stage filing under 35 U.S.C. 371 of International Application No. PCT/US2013/025541, filed Feb. 11, 2013, which claims the benefit of priority of U.S. Provisional Patent Application No. 61/596,869, filed Feb. 9, 2012, and of International Application No. PCT/US2012/069831, filed Dec. 14, 2012, all of which are incorporated herein by reference in their entireties.
This invention was made with United States government support awarded by the National Institutes of Health grant number NCRR COBRE 8P30GM103450 and INBRE GM103429. The United States may have certain rights in this invention.
| Number | Name | Date | Kind |
|---|---|---|---|
| 5914126 | Li et al. | Jun 1999 | A |
| 6362163 | Gardella et al. | Mar 2002 | B1 |
| 8450273 | Sakon et al. | May 2013 | B2 |
| 8617543 | Huang et al. | Dec 2013 | B2 |
| 9062300 | Gensure et al. | Jun 2015 | B2 |
| 9248164 | Uchida et al. | Feb 2016 | B2 |
| 9354240 | Yamagata et al. | May 2016 | B2 |
| 9526765 | Ponnapakkam et al. | Dec 2016 | B2 |
| 9528099 | Gensure et al. | Dec 2016 | B2 |
| 9579273 | Ponnapakkam et al. | Feb 2017 | B2 |
| 9757435 | Herber | Sep 2017 | B2 |
| 10111983 | Shimp | Oct 2018 | B2 |
| 10202434 | Gensure | Feb 2019 | B2 |
| 10213488 | Ponnapakkam et al. | Feb 2019 | B2 |
| 10358471 | Gensure | Jul 2019 | B2 |
| 10519213 | Gensure | Dec 2019 | B2 |
| 20020102709 | Ishikawa et al. | Aug 2002 | A1 |
| 20020164719 | Hall et al. | Nov 2002 | A1 |
| 20030187232 | Hubbell et al. | Oct 2003 | A1 |
| 20040053368 | Ishikawa et al. | Mar 2004 | A1 |
| 20040220094 | Skinner et al. | Nov 2004 | A1 |
| 20050119183 | Wells et al. | Jun 2005 | A1 |
| 20050124537 | Kostemuik et al. | Jun 2005 | A1 |
| 20050180986 | Rich et al. | Aug 2005 | A1 |
| 20060014687 | Crine et al. | Jan 2006 | A1 |
| 20060257376 | Scadden et al. | Nov 2006 | A1 |
| 20080108562 | Riviere et al. | May 2008 | A1 |
| 20090305352 | Dai et al. | Dec 2009 | A1 |
| 20100129341 | Sakon et al. | May 2010 | A1 |
| 20100159564 | Dwulet et al. | Jun 2010 | A1 |
| 20130287759 | Muñoz Montano | Oct 2013 | A1 |
| 20130337017 | Gensure et al. | Dec 2013 | A1 |
| 20140377215 | Ponnapakkam et al. | Dec 2014 | A1 |
| 20150038423 | Ponnapakkam et al. | Feb 2015 | A1 |
| 20150284701 | Gensure et al. | Oct 2015 | A1 |
| 20160339078 | Hamill et al. | Nov 2016 | A1 |
| 20170101457 | Gensure et al. | Apr 2017 | A1 |
| 20170106093 | Ponnapakkam et al. | Apr 2017 | A1 |
| 20170204390 | Ponnapakkam et al. | Jul 2017 | A1 |
| 20180055918 | Herber | Mar 2018 | A1 |
| 20180140742 | Uchida et al. | May 2018 | A1 |
| Number | Date | Country |
|---|---|---|
| 0207751 | Jan 1987 | EP |
| 2002-58485 | Feb 2002 | JP |
| 2004-500838 | Jan 2004 | JP |
| 2010-523671 | Jul 2010 | JP |
| WO 2000006195 | Feb 2000 | WO |
| WO 2000049159 | Aug 2000 | WO |
| WO 2003052091 | Jun 2003 | WO |
| WO 2004071543 | Aug 2004 | WO |
| WO 2006072623 | Jul 2006 | WO |
| WO 2008124166 | Oct 2008 | WO |
| WO 2009014854 | Jan 2009 | WO |
| WO 2010087397 | Aug 2010 | WO |
| WO 2011142425 | Nov 2011 | WO |
| WO 2012124338 | Sep 2012 | WO |
| WO 2012157339 | Nov 2012 | WO |
| WO 2013090770 | Jun 2013 | WO |
| WO 2013120060 | Aug 2013 | WO |
| WO 2016060252 | Apr 2016 | WO |
| Entry |
|---|
| Komarova, S.V., “Mathematical model of paracrine interactions between osteoclasts and osteoblasts predicts anabolic action of parathyroid hormone on bone,” Endocrinology. (2005) 146(8):3589-95. Epub Apr. 28, 2005. |
| Kousteni, S. et al., “The cell biology of parathyroid hormone in osteoblasts,” Curr Osteoporos. Rep. (2008) 6(2):72-6. |
| Kroll, M.H., “Parathyroid hormone temporal effects on bone formation and resorption,” Bull Math Biol. (2000) 62(1):163-88. |
| Lemaire, V. et al., “Modeling the interactions between osteoblast and osteoclast activities in bone remodeling,” J Theor Biol. (2004) 229(3):293-309. |
| Li, X. et al., “Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis,” J Biol Chem. (2007) 282(45):33086-97. Epub Aug. 9, 2007. |
| Li, X. et al., “In vivo parathyroid hormone treatments and RNA isolation and analysis,” Methods Mol Biol. (2008) 455:79-87. |
| Liu, J. et al., “Intermittent PTH administration: a novel therapy method for periodontitis-associated alveolar bone loss,” Med Hypotheses. (2009) 72(3):294-6. Epub Nov. 30, 2008. |
| Locklin, R.M. et al., “Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone,” J Cell Biochem. (2003) 89(1):180-90. |
| Locus BAA06251 (GI 710023), Collagenase precursor from Clostridium histolyticum, Jan. 30, 2003. This amino acid sequence is disclosed in this application as SEQ ID No. 6. The sequence of residues 901-1021 of BAA06251 corresponds to the collagen binding domain included in the fusion protein of SEQ ID No. 1. |
| Locus EAW68494 (GI 119588900), Parathyroid hormone isoform from Homo sapiens, Dec. 18, 2006. Residues 64-147 of EAW68494 correspond to the PTH of SEQ ID No. 7. |
| Lotinun, S. et al., “Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression,” Endocrine. (2002) 17(1):29-36. |
| Lotinun, S. et al., “Triazolopyrimidine (trapidil), a platelet-derived growth factor antagonist, inhibits parathyroid bone disease in an animal model for chronic hyperparathyroidism,” Endocrinology. (2003) 144(5):2000-7. |
| Lumachi, F. et al., “Lumbar spine bone mineral density changes in patients with primary hyperparathyroidism according to age and gender,” Ann N Y Acad Sci. (2007) 1117:362-6. Epub Jul. 26, 2007. |
| Ma, Y.L. et al., “Catabolic effects of continuous human PTH (1—38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation,” Endocrinology (2001) 142(9):4047-54. |
| Machado Do Reis, L. et al., “Accentuated osteoclastic response to parathyroid hormone undermines bone mass acquisition in osteonectin-null mice,” Bone (2008) 43(2):264-73. Epub Apr. 13, 2008. |
| Malluche, H.H. et al., “Endogenous calcitonin does not protect against hyperparathyroid bone disease in renal failure,” Miner. Electrolyte Metab. (1986) 12(2):113-8. |
| Malluche, H.H. et al., “Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome,” J Clin Invest. (1979) 63(3):494-500. |
| Malluche, H.H. et al., “Influence of the parathyroid glands on bone metabolism,” Eur J Clin Invest. (2006) 36(Suppl 2):23-33. |
| Malluche, H.H. et al., “Effects of long-term infusion of physiologic doses of 1-34 PTH on bone” Am J Physiol. (1982) 242(2):F197-201. |
| Masi, L. et al., “Molecular, biochemical and cellular biology of PTH anabolic action,” J Endocrinol Invest. (2005) 28(8 Suppl):37-40. |
| Mathias, R. et al., “Renal bone disease in pediatric and young adult patients on hemodialysis in a children's hospital,” J Am Soc Nephrol. (1993) 3(12):1938-46. |
| Matsushita, O. et al., “A study of the collagen-binding domain of a 116-kDa Clostridium histolyticum collagenase,” J Biological Chem (1998) 273(6):3643-3648. |
| Matsushita, O. et al., “Gene duplication and multiplicity of C. Histolyticum collagenases,” J. Bacteriol. (1999) 181:923-933. |
| Matsushita, O. et al., “Substrate recognition by the collagen-binding domain of Clostridium histolyticum class I collagenase,” J of Biological Chem (2001) 276(12):8761-8770. |
| Matsushita, O., “Studies on the Clostridal Collagenases,” Nippon Saikingaku Zasshi (1999) 54(4):753-761. |
| McCauley, L.K. et al., “PTH/PTHrP receptor is temporally regulated during osteoblast differentiation and is associated with collagen synthesis,” J Cell Biochem (1996) 61:638-647. |
| McCauley, L.K. et al., “Proto-oncogene c-fos is transcriptionally regulated by parathyroid hormone (PTH) and PTH-related protein in a cyclic adenosine monophosphate-dependent manner in osteoblastic cells,” Endocrinology (1997) 138(12):5427-33. |
| McCauley, L.K. et al., “Parathyroid hormone stimulates fra-2 expression in osteoblastic cells in vitro and in vivo,” Endocrinology (2001) 142(5):1975-81. |
| Minisola, S. et al., “Trabecular bone mineral density in primary hyperparathyroidism: relationship to clinical presentation and biomarkers of skeletal turnover,” Bone Miner. (1993) 20(2):113-23. |
| Minisola, S. et al., “Uneven deficits in vertebral bone density in postmenopausal patients with primary hyperparathyroidism as evaluated by posterior-anterior and lateral dual-energy absorptiometry,” Osteoporos Int. (2002) 13(8):618-23. |
| Mitlak, B.H. et al., “Asymptomatic primary hyperparathyroidism,” J Bone Miner Res. (1991) 6(Suppl 2):S103-10; discussion S121-4. |
| Miyachi, Y. et al., “Long-term safety and efficacy of high-concentration (20 mug/g) tacalcitol ointment in psoriasis vulgaris,” Eur J Dermatol (2002) 12(5):463-468. |
| Morley, P. et al., “Anabolic effects of parathyroid hormone on bone,” Trends Endocrinol. Metab. (1997) 8(6):225-31. |
| Morley, P. et al., “Parathyroid hormone: an anabolic treatment for osteoporosis,” Curr Pharm Des. (2001) 7(8):671-87. |
| Murray, E.J. et al., “E64d, a membrane-permeable cysteine protease inhibitor, attenuates the effects of parathyroid hormone on osteoblasts in vitro,” Metabolism (1997) 46(9):1090-4. |
| Nasu, M. et al., “Stimulatory effects of parathyroid hormone and 1,25-dihydroxyvitamin D3 on insulin-like growth factor-binding protein-5 mRNA expression in osteoblastic UMR-106 cells: the difference between transient and continuous treatments,” FEBS Lett. (1997) 409(1):63-6. |
| Neer, R.M. et al., “Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis,” N. Engl. J. Med. (2001) 344(19):1434-1441. |
| Nemeth, E.F., “Pharmacological regulation of parathyroid hormone secretion,” Curr Pharm. Des. (2002) 8(23):2077-87. |
| Nilsson, P., “Bone disease in renal failure. Clinical and histomorphometric studies,” Scand J Urol Nephrol Suppl. (1984) 84:1-68. |
| Nishi, N. et al., “Collagen-binding growth factors: Production and characterization of functional fusion proteins having a collagen-binding domain,” PNAS (1998) 95(12):7018-7023. |
| Nomura, R. et al., “Contribution of the Collagen-Binding Proteins of Streptococcus mutans to Bacterial Colonization of Inflamed Dental Pulp” PLoS One (2016) 11(7):e0159613. |
| O'Brien, C.A. et al., “IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice,” Am J Physiol Endocrinol Metab. (2005) 289(5):E784-93. Epub Jun. 14, 2005. |
| Okazaki, R., “Parathyroid hormone—its mechanisms of action and issues on clinical application,” Clin Calcium. (2005) 15(5):845-51. |
| Olgaard, K. et al., “Can hyperparathyroid bone disease be arrested or reversed?,” Clin J Am Soc Nephrol. (2006) l(3):367-73. Epub Mar. 29, 2006. |
| Onyia, J.E. et al., “Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray,” J Cell Biochem. (2005) 95(2):403-18. |
| Owens, R.J. et al., “Mapping the collagen-binding site of human fibronectin by expression in Escherichia coli,” The EMBO Journal (1986) 5(11)2825-2830. |
| Paillard, M. et al., “Determinants of parathormone secretion in primary hyperparathyroidism,” Horm Res. (1989) 32(1-3):89-92. |
| Parfitt, A.M., “The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part IV of IV parts: The state of the bones in uremic hyperaparathyroidism—the mechanisms of skeletal resistance to PTH in renal failure and pseudohypoparathyroidism and the role of PTH in osteoporosis, osteopetrosis, and osteofluorosis,” Metabolism. (1976) 25(10):1157-88. |
| Parfitt, A.M. et al., “Hypercalcemia due to constitutive activity of the parathyroid hormone (PTH)/PTH-related peptide receptor: comparison with primary hyperparathyroidism,” J Clin Endocrinol Metab. (1996) 81(10):3584-8. |
| Peters, E.M.J. et al., “A new strategy for modulating chemotherapy-induced alopecia, using PTH/PTHrP receptor agonist and antagonist,” J Invest Dermatol (2001) 117(2):173-178. |
| Pettway, et al., “Anabolic actions of PTH (1-34): Use of a novel tissue engineering model to investigate temporal effects on bone,” Bone (2005) 36(6):959-970. |
| Phelps, E. et al., “Parathyroid hormone induces receptor activity modifying protein-3 (RAMP3) expression primarily via 3′,5′-cyclic adenosine monophosphate signaling in osteoblasts,” Calcif Tissue Int. (2005) 77(2):96-103. Epub Aug. 11, 2005. |
| Philominathan et al., “Unidirectional binding of Clostridial Colleagenase to Triple Helical Substrates,” Journal of Biological Chemistry (2009) 284(16):10868-10876. |
| Philominathan et al., “Bacterial collagen-binding domain targets undertwisted regions of collagen,” Protein Sci. (2012) 21(10):1554-65. |
| Pirih, F.Q. et al., “Parathyroid hormone induces the NR4A family of nuclear orphan receptors in vivo,” Biochem Biophys Res Commun. (2005) 332(2):494-503. |
| Podbesek, R. et al., “Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds,” Endocrinology (1983) 112(3):1000-6. |
| Ponnapakkam, T. et al., “A fusion protein of parathyroid hormone (PTH) and a collagen binding domain shows superior efficacy and longer duration of action compared to PTH(1-34) as an anabolic bone agent in normal female mice,” Bone (2009) 44:S35-S36. |
| Ponnapakkam, T., et al., “Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice,” Calcif Tissue Int.2011;88:511-520. |
| Ponnapakkam, T. et al., “A Single Injection of the Anabolic Bone Agent, Parathyroid Hormone-Collagen Binding Domain (PTH-CBD), Results in Sustained Increases in Bone Mineral Density for up to 12 Months in Normal Female Mice” Calcified Tissue (2012) 91(30:196-203. |
| Poole, K.E. et al., “Parathyroid hormone—a bone anabolic and catabolic agent,” Curr Opin Pharmacol. (2005) 5(6):612-7. Epub Sep. 21, 2005. |
| Potter, L.K. et al., “Response to continuous and pulsatile PTH dosing: a mathematical model for parathyroid hormone receptor kinetics,” Bone (2005) 37(2):159-169. |
| Potts, J.T., “Parathyroid hormone: past and present,” J Endocronology (2005) 187:311-325. |
| Qin, L. et al., “Parathyroid hormone: a double-edged sword for bone metabolism,” Trends Endocrinol Metab. (2004) 15(2):60-5. |
| Rattanakul, C. et al., “Modeling of bone formation and resorption mediated by parathyroid hormone: response to estrogen/PTH therapy” Biosystems (2003) 70(1):55-72. |
| Richardson, M.L. et al., “Bone mineral changes in primary hyperparathyroidism,” Skeletal Radiol. (1986) 15(2):85-95. |
| Rickard, D.J. et al., “Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells,” Bone (2006) 39(6):1361-1372. Epub Aug. 10, 2006. |
| Rixon, R.H. et al., “Parathyroid hormone fragments may stimulate bone growth in ovariectomized rats by activating adenylyl cyclase,” J Bone Miner Res. (1994) 9(8):1179-89. |
| Robinson, J.A. et al., “Identification of a PTH regulated gene selectively induced in vivo during PTH-mediated bone formation,” J Cell Biochem. (2006) 98(5):1203-20. |
| Rosen, C.J., “The cellular and clinical parameters of anabolic therapy for osteoporosis,” Crit Rev Eukaryot Gene Expr. (2003) 13(1):25-38. |
| Rubin, M.R. et al., “The potential of parathyroid hormone as a therapy for osteoporosis,” Int J Fertil Womens Med. (2002) 47(3):103-15. |
| Rubin, M. et al., “The anabolic effects of parathyroid hormone therapy,” Osteoporosis International (2002) 13(4):267-277. |
| Rubin, M.R. et al., “The anabolic effects of parathyroid hormone therapy,” Clin Geriatr Med. (2003) 19(2):415-32. |
| Safer, J.D. et al., “A topical parathyroid hormone/parathyroid hormone-related peptide receptor antagonist stimulates hair growth in mice,” Endocrinology (2007)148:1167-1170. |
| Schaefer, F., “Pulsatile parathyroid hormone secretion in health and disease,” Novartis Found Symp. (2000) 227:225-39; discussion 239-43. |
| Schilli, M.B. et al., “Control of hair growth with parathyroid hormone (7-34),” J Invest Dermatol (1997) 108:928-932. |
| Schluter, K.-D. et al., “A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ETA receptors,” British Journal of Pharmacology (2001) 132:427-432. |
| Schmitt, C.P. et al., “Intermittent administration of parathyroid hormone (1-37) improves growth and bone mineral density in uremic rats,” Kidney Int. (2000) 57(4):1484-92. |
| Schmitt, C.P. et al., “Structural organization and biological relevance of oscillatory parathyroid hormone secretion,” Pediatr Nephrol. (2005) 20(3):346-51. Epub Feb. 8, 2005. |
| Schneider, A. et al., “Skeletal homeostasis in tissue-engineered bone,” J Orthop Res. (2003) 21(5):859-64. |
| Seeman, E. et al., “Reconstructing the skeleton with intermittent parathyroid hormone,” Trends Endocrinol Metab. (2001) 12(7):281-3. |
| Sekiguchi, H. et al., “Acceleration of bone formation during fracture healing by poly(pro-hyp-gly)10 and basic fibroblast growth factor containing polycystic kidney disease and collagen-binding domains from Clostridium histolyticum collagenase” J. Biomed Mater Res A. (2016) 104(6):1372-1378. |
| Shen, V. et al., “Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion,” J Bone Miner Res. (2000) 15(4):740-6. |
| Shin, H., et al. Efficacy of Interventions for Prtevention of Chemotherapy-Induced Alopecia: A systematic review and meta-analysis. International Journal of Cancer. 2015. 136: E442-E454. |
| Shinoda, Y. et al., “Mechanisms underlying catabolic and anabolic functions of parathyroid hormone on bone by combination of culture systems of mouse cells,” J. of Cellular Biology (2010) 109(4):755-63. |
| Silver, J. et al., “Harnessing the parathyroids to create stronger bones,” Curr Opin Nephrol Hypertens. (2004) 13(4):471-6. |
| Silverberg, S.J. et al., “Skeletal disease in primary hyperparathyroidism,” J Bone Miner Res., (1989) 4(3):283-91. |
| Skripitz, R. et al., “Parathyroid hormone—a drug for orthopedic surgery?,” Acta Orthop Scand. (2004) 75(6):654-62. |
| Skripitz, R. et al., “Stimulation of implant fixation by parathyroid hormone (I-34)—A histomorphometric comparison of PMMA cement and stainless steel,” J Orthop Res. (2005) 23(6): 1266-70. Epub Jun. 16, 2005. |
| Smajilovic, S. et al., “Effect of intermittent versus continuous parathyroid hormone in the cardiovascular system of rats,” Open Cardiovasc. Med. J. (2010) 4:110-6. |
| Spurney, R.F. et al., “Anabolic effects of a G protein-coupled receptor kinase inhibitor expressed in osteoblasts,” J Clin Invest. (2002) 109(10):1361-71. |
| Stewart, A.F., “PTHrP(1-36) as a skeletal anabolic agent for the treatment of osteoporosis,” Bone (1996) 19(4):303-306. |
| Stracke, S. et al., “Long-term outcome after total parathyroidectomy for the management of secondary hyperparathyroidism,” Nephron Clin Pract. (2009) 111(2):c102-9. Epub Jan. 13, 2009. |
| Strewler, G.J., “Local and systemic control of the osteoblast,” J. of Clin. Invest. (2001) 107:271-272. |
| Suttamanatwong, S. et al., “Regulation of matrix Gla protein by parathyroid hormone in MC3T3-E1 osteoblast-like cells involves protein kinase A and extracellular signal-regulated kinase pathways,” J Cell Biochem. (2007) 102(2):496-505. |
| Suttamanatwong, S. et al., “Sp proteins and Runx2 mediate regulation of matrix gla protein (MGP) expression by parathyroid hormone,” J Cell Biochem. (2009) 107(2):284-92. |
| Suzuki, A. et al., “PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3beta in osteoblastic Saos-2 cells,” J Cell Biochem. (2008) 104(1):304-17. |
| Abdelhadi, M. et al., “Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism,” J Clin Endocrinol Metab. (1998) 83(11):3845-51. |
| Abe, Y. et al., “Enhancement of graft bone healing by intermittent administration of human parathyroid hormone (1-34) in a rat spinal arthrodesis model,” Bone (2007) 41(5):775-785. |
| Abshirini, H. et al., “Pathologic fractures: a neglected clinical feature of parathyroid adenoma,” Case (2010) p. 357029. Epub Nov. 29, 2010. |
| Akimoto, M. et al., “Effects of CB-VEGF-A injection in rat flap models for improved survival,” (2013) Plast. Reconstr. Surg. 131(4):717-725. |
| Aleksyniene, R. et al., “Parathyroid hormone—possible future drug for orthopedic surgery,” Medicina (Kaunas) (2004) 40(9):842-9. |
| Andrade, M.C., et al., “Bone mineral density and bone histomorphometry in children on long-term dialysis,” Pediatr Nephrol. (2007) 22(10):1767-72. Epub Aug. 7, 2007. |
| Barros, S.P., et al., “Parathyroid hormone protects against periodontitis-associated bone loss,” J Dent Res. (2003) 82(10):791-5. |
| Bauer, R., et al., “Structural comparison of ColH and ColG collagen-binding domains from Clostridium histolyticum,” (2013) Journal of Bacteriology, 195(2), 318-327. |
| Bedi, B., et al., “Inhibition of antigen presentation and T cell costimulation blocks PTH-induced bone loss,” Ann N Y Acad Sci. (2010) 1192:215-21. |
| Belinsky, G.S. et al., “Direct measurement of hormone-induced acidification in intact bone,” J Bone Miner Res., (2000) 15(3):550-6. |
| Bellido, T., et al., “Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis,” Endocrinology (2005) 146(11):4577-83. Epub Aug. 4, 2005. |
| Bergenstock, M.K. et al., “Parathyroid hormone stimulation of noncanonical Wnt signaling in bone,” Ann N Y Acad Sci. (2007) 1116:354-9. |
| Bergwitz, C. et al., “Rapid desensitization of parathyroid hormone dependent adenylate cyclase in perifused human osteosarcoma cells (SaOS-2),” Biochem Biophys Acta. (1994) 1222(3):447-56. |
| Bianchi, E.N. et al., “Beta-arrestin2, regulates parathyroid hormone effects on a p38 MAPK and NFkappaB gene expression network in osteoblasts” Bone (2009) 45(4):716-25. Epub Jun. 25, 2009. |
| Bilezikian, J.P. et al., “Asymptomatic primary hyperparathyroidism: new issues and new questions—bridging the past with the future,” J Bone Miner Res. (2002) 17(Suppl 2):N57-67. |
| Bilezikian, J.P. et al., “Characterization and evaluation of asymptomatic primary hyperparathyroidism,” J Bone Miner Res. (1991) 6(Suppl 2):S85-9; discussion S121-4. |
| Blachowicz, A. et al., “Serum 1-84 and 7-84 parathyroid hormone concentrations and bone in patients with primary hyperparathyroidism,” Langenbecks Arch Surg. (2008) 393(5):709-13. Epub Jul. 11, 2008. |
| Buargub, M.A. et al., “Prevalence and pattern of renal osteodystrophy in chronic hemodialysis patients: a cross sectional study of 103 patients,” Saudi J Kidney Dis Transpl. (2006) 17(3):401-7. |
| Calvi, L.M. et al., “Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone,” J. Clin. Invest. (2001)107:277-286. |
| Calvi, L.M. et al., “Osteoblastic cells regulate the haematopoietic stem cell niche,” Nature (2003) 425:841-846. |
| Canalis, E., “Effect of hormones and growth factors on alkaline phosphatase activity and collagen synthesis in cultured rat calvariae,” Metabolism (1983) 32(1):14-20. |
| Canalis, E. et al., “Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures,” J Clin Invest. (1989) 83(1):60-5. |
| Carter, P.H. et al., “Selective and Nonselective Inverse Agonists for Constitutively Active Type-1 Parathyroid Hormone Receptors: Evidence for Altered Receptor Conformations,” Endocrinology (2001) 142(4):1534-1545. |
| Chan, H.W. et al., “Prospective study on dialysis patients after total parathyroidectomy without autoimplant,” Nephrology (2009) 15(4):441-7. |
| Chen, B. et al., “Homogeneous osteogenesis and bone regeneration by demineralized bone matrix loading with collagen-targeting bone morphogenetic protein-2,” Biomaterials (2007) 28:1027-1035. |
| Chen, Q. et al., “Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects,” J Clin Endocrinol Metab. (2003) 88(10):4655-8. |
| Cherian, P.P. et al., “Role of gap junction, hemichannels, and connexin 43 in mineralizing in response to intermittent and continuous application of parathyroid hormone,” Cell Commun Adhes. (2008) 15(1):43-54. |
| Chevalley, T. et al., “Bone and hormones. Effects of parathyroid hormone on the bone,” Presse Med. (1999) 28(10):547-53. |
| Cohen, A. et al., “Osteoporosis in adult survivors of adolescent cardiac transplantation may be related to hyperparathyroidism, mild renal insufficiency, and increased bone turnover,” J Heart Lung Transplant. (2005) 24(6):696-702. |
| Compston, J.E., “Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure,” Bone (2007) 40(6):1447-1452. |
| Cormier, C., “Parathyroid hormone in osteoporosis,” Presse Med. (2006) 35(3 Pt 2):495-501. |
| Corsi, A. et al., “Osteomalacic and hyperparathyroid changes in fibrous dysplasia of bone: core biopsy studies and clinical correlations,” J Bone Miner Res. (2003) 18(7):1235-46. |
| Cosman, F., “Parathyroid hormone treatment for osteoporosis,” Current Opinion in Endocrinology, Diabetes & Obesity (2008) 15:495-501. |
| Cundy, T. et al., “Hyperparathyroid bone disease in chronic renal failure,” Ulster Med J. (1985) 54(Suppl):S34-43. |
| Datta, N.S. et al., “Distinct roles for mitogen-activated protein kinase phosphatase-1 (MKP-1) and ERK-MAPK in PTH1R signaling during osteoblast proliferation and differentiation,” Cell (2010) 22(3):457-66. Epub. |
| Deal, C., “The use of intermittent human parathyroid hormone as a treatment for osteoporosis,” Curr Rheumatol Rep. (2004) 6(1): 49-58. |
| Demiralp, B. et al., “Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos,” Endocrinology (2002) 143(10):4038-47. |
| Dobnig, H. et al., “The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats,” Endocrinology (1997) 138(11):4607-12. |
| Drake, M.T. et al., “Parathyroid hormone increases the expression of receptors for epidermal growth factor in UMR 106-01 cells,” Endocrinology (1994) 134(4):1733-7. |
| Endo, K. et al., “1,25-dihydroxyvitamin D3 as well as its analogue OCT lower blood calcium through inhibition of bone resorption in hypercalcemic rats with continuous parathyroid hormone-related peptide infusion,” J Bone Miner Res. (2000) 15(1):175-81. |
| Etoh, M. et al., “Repetition of continuous PTH treatments followed by periodic withdrawals exerts anabolic effects on rat bone,” J Bone Miner Metab. (2010) 28(6):641-649. |
| Farhanigan, M.E., et al. Treatment of Alopecia Areata in the United States: A Retrospective Cross-Sectional Study.J Drugs Dermatology. 2015 14(9):1012-4. |
| Fitzpatrick, L.A. et al., “Acute primary hyperparathyroidism,” Am J Med. (1987) 82(2):275-82. |
| Fleming, A. et al., “High-throughput in vivo screening for bone anabolic compounds with zebrafish,” J Biomol Screen. (2005) 10(8):823-31. Epub Oct. 18, 2005. |
| Fouda, M.A., “Primary hyperparathyroidism: King Khalid University Hospital Experience,” Ann Saudi Med. (1999) 19(2):110-5. |
| Fox, J. et al., “Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys,” Bone (2007) 41(3):321-330. |
| Fraher, L.J. et al., “Comparison of the biochemical responses to human parathyroid hormone-(1-31)NH2 and hPTH-(1-34) in healthy humans,” J Clin Endocrinol Metab. (1999) 84(8):2739-43. |
| Frolik, C.A et al., “Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure,” Bone (2003) 33(3):372-379. |
| Fujita, T., “Parathyroid hormone in the treatment of osteoporosis,” BioDrugs (2001) 15(11):721-728. |
| Fukayama, S. et al., “New insights into interactions between the human PTH/PTHrP receptor and agonist/antagonist binding,” Am. J. Physiol. Endocrinol. Metab. (1998) 274:297-303. |
| Gao, Y. et al., “T cells potentiate PTH-induced cortical bone loss through CD40L signaling,” Cell Metab. (2008) 8(2):132-45. |
| Gardella, T.J. et al., “Converting Parathyroid Hormone-related Peptide (PTHrP) into a Potent PTH-2 Receptor Agonist,” J. of Biological Chemistry, (1996) 271(33):19888-19893. |
| Gensure, R.C. et al., “Parathyroid hormone and parathyroid hormone-related peptide, and their receptors,” Biochem Biophys Res Commun. (2005) 328(3):666-78. |
| Gensure, R.C. et al., “Parathyroid hormone without parathyroid glands,” Endocrinology (2005) 146(2):544-546. |
| Gensure, R.C. et al., “Parathyroid hormone-related peptide and the hair cycle—is it the agonists or the antagonists that cause hair growth?” (2014) Experimental Dermatology, 23(12):865-867. |
| Gevers, E.F.et al., “Bone marrow adipocytes: a neglected target tissue for growth hormone,” Endocrinology (2002) 143(10):4065-73. |
| Goltzman, D., “Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone,” Arch Biochem Biophys. (2008) 473(2):218-24. Epub Mar. 10, 2008. |
| Gopalakrishnan, R. et al., “Role of matrix Gla protein in parathyroid hormone inhibition of osteoblast mineralization,” Cells Tissues Organs (2005) 181(3-4):166-75. |
| Gosavi, A. et al., “An unusual presentation of parathyroid adenoma—a case report,” Indian J Pathol Microbiol. (2005) 48(2):208-10. |
| Gu, W.X. et al., “Mutual up-regulation of thyroid hormone and parathyroid hormone receptors in rat osteoblastic osteosarcoma 17/2.8 cells,” Endocrinology (2001) 142(1):157-64. |
| Hall, A.K. et al., “The effects of parathyroid hormone on osteoblast-like cells from embryonic chick calvaria,” Acta Endocrinol (Copenh). (1985) 108(2):217-23. |
| Han, B. et al., “Collagen-targeted BMP3 fusion proteins arrayed on collagen matrices or porous ceramics impregnated with Type I collagen enhance osteogenesis in a rat cranial defect model,” J Orthopaedic Research (2002) 20:747-755. |
| Headley, C.M., “Hungry bone syndrome following parathyroidectomy,” Anna J., (1998) 25(3):283-9; quiz 290-1. |
| Heath, H., 3rd, “Clinical spectrum of primary hyperparathyroidism: evolution with changes in medical practice and technology,” J Bone Miner Res. (1991) 6(Suppl 2):S63-70; discussion S83-4. |
| Hoare, S.R. et al., “Specificity and stability of a new PTH1 receptor antagonist, mouse TIP(7-39),” Peptides (2002) 23(5):989-998. |
| Hock, J.M. et al., “Human parathyroid hormone-(1-34) increases bone mass in ovariectomized and orchidectomized rats,” Endocrinology (1988) 122(6):2899-2904. |
| Hock, J.M. et al., “Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone,” J Bone Miner Res. (1992) 7(1):65-72. |
| Holick, M.F. et al., “Topical PTH (1-34) is a novel, safe and effective treatment for psoriasis: a randomized self-controlled trial and an open trial,” (2003) British J. Dermatology 149:370-376. |
| Homme, M. et al., “Differential regulation of RGS-2 by constant and oscillating PTH concentrations,” Calcif Tissue Int. (2009) 84(4):305-12. Epub Feb. 20, 2009. |
| Horwitz, M.J. et al., “Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose,” J Clin Endocrinol Metab. (2010) 95(3):1279-87. |
| Horwitz, M.J. et al., “Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D,” J Bone Miner Res. (2005) 20(10):1792-803. Epub Jun. 6, 2005. |
| Hruska, K.A. et al., “Regulation of skeletal remodeling by parathyroid hormone,” Contrib Nephrol. (1991) 91:38-42. |
| Iida-Klein, A. et al., “Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice,” J Endocrinol. (2005) 186(3):549-57. |
| Ishii, H. et al., “Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-tumover bone and osteomalacia,” Bone (2000) 26(2):175-82. |
| Ishikawa, T. et al., “Delivery of a growth factor fusion protein having collagen-binding activity to wound tissues,” Artif. Organs (2003) 27(2):147-154. |
| Ishikawa, T. et al., “Production of a biologically active epidermal growth factor fusion protein with high collagen affinity,” J. Biochem. (2001) 129(4)627-633. |
| Ishizuya, T. et al., “Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells,” J Clin Invest. (1997) 99(12):2961-70. |
| Ito, M., “Parathyroid hormone and bone quality,” Clin Calcium. (2005) 15(12):31-7. |
| Ito, M., “Parathyroid and bone: Effect of parathyroid hormone on bone quality,” Clin Calcium. (2007) 17(12):1858-64. |
| Jansen, P.L. et al., “Hernia disease and collagen gene regulation: are there clues for intervention?” Hernia (2006) 10:486-491. |
| Jeon, E. et al., “Engineering and application of collagen-binding fibroblast growth factor 2 for sustained release,” (2013) J. of Biomed. Materials Research: Part A. |
| Jilka, R.L., “Molecular and cellular mechanisms of the anabolic effect of intermittent PTH,” Bone (2007) 40(6):1434-1446. Epub Apr. 6, 2007. |
| Jilka, R.L. et al., “Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms,” J Bone Miner Res. (2010) 25(11):2427-37. |
| Kaji, H., “Parathyroid and bone: Effects of parathyroid hormone on bone resorption and formation: differences between intermittent and continuous treatment,” Clin Calcium., (2007) 17(12):1836-42. |
| Katikaneni et al., “Treatment for chemotherapy-induced alopecia in mice using parathyroid hormone agonists and antagonists linked to coolagen binding domain,” Int. J. Cancer (2012) 131(5):E813-821. |
| Katikaneni et al., “Therapy for alopecia areata in mice using parathyroid hormone agonists and antagonists, linked to a collagen-binding domain,” J. of Investigative Dermatology Symposium Proceedings, (2013) 16(1):S61-S62. |
| Katikaneni R., et al. Parathyroid hormone linked to a collagen binding domain (PTH-CBD) promotes hair growth in a mouse model of chemotherqapy-induced alopecia in a dose-dependent manner. Anticancer Drugs. 2014. 25(7): 819-825. |
| Katikaneni, R. et al. Treatment and Prevention of Chemotherapy-induced alopecia with PTH-CBD, a collagen targeted parathyroid hormone analog, in a non-depilated mouse model. Anticancer Drugs. 2014. 25(1): 30-38. |
| Katikaneni, R. et al. Therapy for alopecia Areata in Mice by Stimulating the Hair Cycle with Parathyroid Hormone Agonists Linked to a Collagen-Binding Domain. The Journal of Investigative Dermatology Symposium. 2015. 17: 13-15. |
| Kaye, M. et al., “Elective total parathyroidectomy without autotransplant in end-stage renal disease,” Kidney Int. (1989) 35(6):1390-9. |
| Khan, A. et al., “Primary hyperparathyroidism: pathophysiology and impact on bone,” Cmaj. (2000) 163(2):184-7. |
| Kido, S. et al., “Mechanism of PTH actions on bone,” Clin Calcium. (2003) 13(1):14-8. |
| Kistler, H., “Primary hyperparathyroidism: An analysis of 152 patients with special references to acute life threatening complications (acute hyperparathyroidism),” Schweiz Med Wochenschr. (1976) 106(Suppl 3):1-61. |
| Kitazawa, R. et al., “Effects of continuous infusion of parathyroid hormone and parathyroid hormone-related peptide on rat bone in vivo: comparative study by histomorphometry,” Bone Miner. (1991) 12(3):157-66. |
| Klempa, I., “Treatment of secondary and tertiary hyperparathyroidism—surgical viewpoints,” Chirurg. (1999) 70(10):1089-101. |
| Koh, A.J. et al., “3′,5′-Cyclic adenosine monophosphate activation in osteoblastic cells: effects on parathyroid hormone-1 receptors and osteoblastic differentiation in vitro,” Endocrinology (1999) 140(7):3154-62. |
| Swarthout, J.T. et al., “Parathyroid hormone-dependent signaling pathways regulating genes in bone cells,” Gene (2002) 282(1-2):1-17. |
| Swarthout, J.T. et al., “Stimulation of extracellular signal-regulated kinases and proliferation in rat osteoblastic cells by parathyroid hormone is protein kinase C-dependent,” J Biol Chem. (2001) 276(10):7586-92. Epub Dec. 6, 2000. |
| Takada, H. et al., “Response of parathyroid hormone to anaerobic exercise in adolescent female athletes,” Acta Paediatr Jpn. (1998) 40(1):73-7. |
| Takasu, H. et al., “Dual signaling and ligand selectivity of the human PTH/PTHrP receptor,” J Bone Miner Res. (1999) 14(1):11-20. |
| Talmage, R.V. et al., “Calcium homeostasis: reassessment of the actions of parathyroid hormone,” Gen Comp Endocrinol. (2008) 156(1):1-8. Epub Nov. 12, 2007. |
| Tam, C.S. et al., “Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration,” Endocrinology (1982) 110(2):506-12. |
| Tawfeek, H. et al., “Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss,” PLoS (2010) 5(8):e12290. |
| Tokumoto, M. et al., “Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor, calcium sensing receptor, and cell cycle regulating factors,” Ther Apher Dial. (2005) 9(Suppl 1):S27-34. |
| Tollin, S.R. et al., “Serial changes in bone mineral density and bone turnover after correction of secondary hyperparathyroidism in a patient with pseudohypoparathyroidism type Ib,” J Bone Miner Res. (2000) 15(7):1412-6. |
| Toyoshima, T. et al., “Collagen-binding domain of a Clostridium histolyticum collagenase exhibits a broad substrate spectrum both in vitro and in vivo,” Connective Tissue Research (2001) 42(4):281-290. |
| Uzawa, T. et al., “Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1-34) on rat bone,” Bone (1995) 16(4):477-84. |
| Vanstone, M.B. et al., “Rapid correction of bone mass after parathyroidectomy in an adolescent with primary hyperparathyroidism,” J. Clin Endocrinol. Metab. (2011) 96(2): E347-50. Epub Nov. 24, 2010. |
| Wan, Q. et al., “Intra-articular injection of parathyroid hormone in the temporomandibular joint as a novel therapy for mandibular asymmetry,” Med Hypotheses (2009) 74(4):685-7. |
| Wang, C.A. et al., “Natural history of parathyroid carcinoma. Diagnosis, treatment, and results,” Am J Surg. (1985) 149(4):522-7. |
| Wang, Y. et al., “A theoretical model for simulating effect of parathyroid hormone on bone metabolism at cellular level,” Mol Cell Biomech. (2009) 6(2):101-12. |
| Wang, Y. et al., “Gender differences in the response of CD-1 mouse bone to parathyroid hormone: potential role of IGF-I,” J Endocrinol. (2006) 189(2):279-87. |
| Watson, P.H. et al., “Enhanced osteoblast development after continuous infusion of hPTH(1-84) in the rat,” Bone (1999) 24(2):89-94. |
| Weir, E.C. et al., “Synthetic parathyroid hormone-like protein (1-74) is anabolic for bone in vivo,” Calcif Tissue Int. (1992) 51(1):30-4. |
| Whitfield, J.F., “Taming Psoriatic Keratinocytes-PTHs' uses go up another notch,” J. Cell. Biochem. (2004) 93:251-256. |
| Wilson, J.J. et al., “A bacterial collagen-binding domain with novel calcium-binding motif controls domain orientation,” EMBO Journal (2003) 22(8)1743-1752. |
| Xu, M. et al., “Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice,” Bone (2010) 47(2):341-52. Epub May 13, 2010. |
| Yang, C. et al., “Effects of continuous and pulsatile PTH treatments on rat bone marrow stromal cells,” Biochem Biophys Res Commun. (2009) 380(4):791-6. Epub Feb. 3, 2009. |
| Yoshihara, K. et al., “Cloning and nucleotide sequence analysis of the coIH gene from Clostridium histolyticum encoding a collagenase and a gelatinase,” J Bacteriol (1994) 176:6489-6496. |
| Younes, N.A. et al., “Laboratory screening for hyperparathyroidism,” Clin Chim Acta. (2005) 353(1-2):1-12. |
| Zang, X.Y. et al., “Effects of parathyroid hormone and estradiol on proliferation and function of human osteoblasts from fetal long bone: An in vitro study,” Chin Med J (Engl). (1994) 107(8):600-3. |
| Zaruba, M.M. et al., “Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival,” Cardiovasc Res (2008) 77(4):722-731. |
| Zhou, H. et al., “Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice,” Bone (2003) 32(5):513-520. |
| International Search Report and Written Opinion of the International Searching Authority for Application No. PCT/US08/004589 dated Oct. 28, 2008 (17 pages). |
| Extended European Search Report for Application No. 08742686.2 dated Aug. 4, 2010 (8 pages). |
| United States Patent Office Action for U.S. Appl. No. 12/594,547 dated Aug. 6, 2012 (12 pages). |
| International Search Report and Written Opinion of the International Searching Authority for Application No. PCT/US12/69831 dated Mar. 14, 2013 (12 pages). |
| International Search Report and Written Opinion of the International Searching Authority for Application No. PCT/US2013/25541 dated Jun. 17, 2013 (16 pages). |
| Restriction Requirement for U.S. Appl. No. 14/365,226 dated Jun. 22, 2015 (8 pages). |
| United States Patent Office Action for U.S. Appl. No. 14/365,226 dated Nov. 24, 2015 (8 pages). |
| United States Patent Office Action for U.S. Appl. No. 14/365,226 dated Jun. 10, 2016 (9 pages). |
| Partial Supplementary European Search Report dated Oct. 1, 2015 (7 pages). |
| Extended European Search Report for Application No. 12857691.5 dated Feb. 8, 2016 (16 pages). |
| Restriction Requirement for U.S. Appl. No. 14/378,067 dated Oct. 23, 2015 (9 pages). |
| United States Patent Office Action for U.S. Appl. No. 14/378,067 dated Feb. 17, 2016 (16 pages). |
| Restriction requirement for U.S. Appl. No. 14/743,629 dated Apr. 20, 2016 (8 pages). |
| Restriction requirement for U.S. Appl. No. 15/407,589 dated Jan. 8, 2018 (5 pages). |
| United States Patent Office Action for U.S. Appl. No. 15/407,589 dated Jun. 26, 2018 (44 pages). |
| United States Patent Office Action for U.S. Appl. No. 15/407,589 dated Jun. 26, 2019 (7 pages). |
| Number | Date | Country | |
|---|---|---|---|
| 20190249163 A1 | Aug 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61570620 | Dec 2011 | US | |
| 61596869 | Feb 2012 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14365226 | US | |
| Child | 15407589 | US | |
| Parent | 16283468 | US | |
| Child | 15407589 | US | |
| Parent | 15386626 | Dec 2016 | US |
| Child | 16283468 | US | |
| Parent | 14378067 | US | |
| Child | 15386626 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15407589 | Jan 2017 | US |
| Child | 16283468 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/US2012/069831 | Dec 2012 | US |
| Child | 14378067 | US |
